<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id>
      <journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id>
      <journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id>
      <journal-id journal-id-type="publisher-id">JAH3</journal-id>
      <journal-id journal-id-type="hwp">ahaoa</journal-id>
      <journal-title-group>
        <journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2047-9980</issn>
      <publisher>
        <publisher-name>John Wiley and Sons Inc.</publisher-name>
        <publisher-loc>Hoboken</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26819251</article-id>
      <article-id pub-id-type="pmc">4859367</article-id>
      <article-id pub-id-type="doi">10.1161/JAHA.115.002497</article-id>
      <article-id pub-id-type="publisher-id">JAH31306</article-id>
      <article-categories>
        <subj-group subj-group-type="overline">
          <subject>Contemporary Review</subject>
        </subj-group>
        <subj-group subj-group-type="heading">
          <subject>Contemporary Reviews</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Overcoming Challenges With Statin Therapy</article-title>
        <alt-title alt-title-type="left-running-head">Spence and Dresser</alt-title>
      </title-group>
      <contrib-group>
        <contrib id="jah31306-cr-0001" contrib-type="author" corresp="yes">
          <name>
            <surname>Spence</surname>
            <given-names>J. David</given-names>
          </name>
          <degrees>MD, FRCPC, FAHA</degrees>
          <xref ref-type="aff" rid="jah31306-aff-0001">
<sup>1</sup>
</xref>
          <xref ref-type="aff" rid="jah31306-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="jah31306-cr-0002" contrib-type="author">
          <name>
            <surname>Dresser</surname>
            <given-names>George K.</given-names>
          </name>
          <degrees>MD, FRCPC</degrees>
          <xref ref-type="aff" rid="jah31306-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="jah31306-aff-0001">
        <label>
          <sup>1</sup>
        </label>
        <named-content content-type="organisation-division">Stroke Prevention &amp; Atherosclerosis Research Centre</named-content>
        <named-content content-type="organisation-division">Robarts Research Institute</named-content>
        <institution>Western University</institution>
        <named-content content-type="city">London</named-content>
        <named-content content-type="country-part">Ontario</named-content>
        <country country="CA">Canada</country>
      </aff>
      <aff id="jah31306-aff-0002">
        <label>
          <sup>2</sup>
        </label>
        <named-content content-type="organisation-division">Division of Clinical Pharmacology</named-content>
        <named-content content-type="organisation-division">Department of Medicine</named-content>
        <institution>Western University</institution>
        <named-content content-type="city">London</named-content>
        <named-content content-type="country-part">Ontario</named-content>
        <country country="CA">Canada</country>
      </aff>
      <author-notes>
        <corresp id="correspondenceTo"><label>*</label><bold>Correspondence to:</bold> J. David Spence, MD, FRCPC, FAHA, Stroke Prevention &amp; Atherosclerosis Research Centre, Robarts Research Institute, University of Western Ontario, 1400 Western Rd, London, Ontario, Canada N6G 2V4. E&#x2010;mail: <email>dspence@robarts.ca</email>, <ext-link ext-link-type="uri" xlink:href="http://www.imaging.robarts.ca/SPARC">www.imaging.robarts.ca/SPARC</ext-link></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>27</day>
        <month>1</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>1</month>
        <year>2016</year>
      </pub-date>
      <volume>5</volume>
      <issue>1</issue>
      <issue-id pub-id-type="doi">10.1002/jah3.2016.5.issue-1</issue-id>
      <elocation-id>e002497</elocation-id>
      <permissions>
        <!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell <copyright-statement>-->
        <copyright-statement content-type="article-copyright">&#xA9; 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.</copyright-statement>
        <license license-type="creativeCommonsBy-nc">
          <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution&#x2010;NonCommercial</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JAH3-5-e002497.pdf"/>
      <kwd-group kwd-group-type="author-generated">
        <kwd id="jah31306-kwd-0001">adverse effects</kwd>
        <kwd id="jah31306-kwd-0002">mitochondrial function</kwd>
        <kwd id="jah31306-kwd-0003">Persistence</kwd>
        <kwd id="jah31306-kwd-0004">statins</kwd>
        <kwd id="jah31306-kwd-0005">ubiquinone</kwd>
      </kwd-group>
      <kwd-group kwd-group-type="subject-categories">
        <title>Subject Categories</title>
        <kwd>Lipids and Cholesterol</kwd>
        <kwd>Secondary Prevention</kwd>
        <kwd>Genetics</kwd>
      </kwd-group>
      <counts>
        <page-count count="13"/>
      </counts>
      <custom-meta-group>
        <custom-meta>
          <meta-name>source-schema-version-number</meta-name>
          <meta-value>2.0</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>component-id</meta-name>
          <meta-value>jah31306</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>January 2016</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>details-of-publishers-convertor</meta-name>
          <meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.8.9 mode:remove_FC converted:04.05.2016</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="jah31306-sec-0001">
      <title>Introduction</title>
      <p>Because statins markedly reduce cardiovascular risk, poor persistence with them is an important clinical problem. If statins were stopped for valid reasons, there may be no opportunity for improvement. However, there are many invalid reasons why patients stop medication, often for symptoms that, although not causally related, are listed in package inserts. Physicians also stop statin therapy for invalid reasons. Several consensus statements, from the Canadian Cardiology Society,<xref rid="jah31306-bib-0001" ref-type="ref">1</xref> the European Atherosclerosis Society,<xref rid="jah31306-bib-0002" ref-type="ref">2</xref> and the National Lipid Association,<xref rid="jah31306-bib-0003" ref-type="ref">3</xref> have reviewed aspects of the adverse effects of statins from various perspectives. In this narrative review, we discuss approaches to helping patients continue needed therapy with statins, based on experience with &gt;50&#xA0;000 patients attending our vascular prevention clinics over many years and from the perspective of clinical pharmacology, including&#xA0;pharmacokinetic and pharmacogenomic factors that impair persistence by worsening causally related effects of statins.</p>
    </sec>
    <sec id="jah31306-sec-0002">
      <title>Importance of Helping Patients Continue to Take Statins</title>
      <p>Adherence markedly affects outcomes in high&#x2010;risk patients. In a recent study of guideline&#x2010;based treatment in peripheral vascular disease,<xref rid="jah31306-bib-0004" ref-type="ref">4</xref> patients adhering to all 4 therapies had a nearly 40% reduction in major cardiovascular events and a 45% reduction in adverse limb events. Inhibitors of hydroxymethylglutaryl&#x2013;coenzyme A reductase (HMG&#x2010;CoA [statins]) markedly reduce cardiovascular risk, particularly in high&#x2010;risk patients. In a large meta&#x2010;analysis of clinical trials, each 1&#x2010;mmol/L reduction of low&#x2010;density lipoprotein (LDL) cholesterol reduced cardiovascular events by just over 20%<xref rid="jah31306-bib-0005" ref-type="ref">5</xref>; importantly, this benefit was independent of the baseline LDL cholesterol. The authors concluded that &#x201C;reduction of LDL cholesterol by 2 to 3&#xA0;mmol/L would reduce occlusive vascular events by about 40% to 50%.&#x201D; Stopping a medication that reduces risk by half is equivalent to doubling risk; it is, therefore, an important problem that so many patients stop statins. Evidence now supports statin treatment in primary prevention,<xref rid="jah31306-bib-0006" ref-type="ref">6</xref> and recent revision of guidelines on treatment of cholesterol<xref rid="jah31306-bib-0007" ref-type="ref">7</xref> will result in statin treatment of many more patients,<xref rid="jah31306-bib-0008" ref-type="ref">8</xref> so persistence with statin therapy is an issue that is increasing in importance. In discussion with patients who believe they are having adverse effects of statins, it is important to evaluate the likelihood that the symptoms are caused by statins or to some other cause. A history of probably causal adverse effects (myalgia, cramps, weakness), particularly with repeat occurrence of adverse effects after re&#x2010;trial of statin following a drug holiday or after a recent increase in dose or potency of statin, will be convincing evidence that the statin is causing the adverse effect; this may be supported by increased blood levels of creatine kinase. Less convincing will a history of symptoms attributed to statin that are unlikely to be causally related, as described later, particularly when the new symptoms arose after a long period of well&#x2010;tolerated statin.</p>
    </sec>
    <sec id="jah31306-sec-0003">
      <title>Problems With Persistence</title>
      <p>In real&#x2010;world practice, as opposed to clinical trials, persistence drops off rapidly; after 3&#xA0;years, &lt;40% of patients persist in taking statins for primary prevention,<xref rid="jah31306-bib-0009" ref-type="ref">9</xref> and for secondary prevention, only 45% are persistent at 3&#xA0;years.<xref rid="jah31306-bib-0010" ref-type="ref">10</xref> This is the case all over the world.<xref rid="jah31306-bib-0011" ref-type="ref">11</xref>, <xref rid="jah31306-bib-0012" ref-type="ref">12</xref> Even in high&#x2010;risk patients such as diabetics, persistence is only &#x2248;50% at 2&#xA0;years.<xref rid="jah31306-bib-0013" ref-type="ref">13</xref> Haukka et&#xA0;al,<xref rid="jah31306-bib-0014" ref-type="ref">14</xref> in a nationwide study in Finland, observed a 5% decrease in mortality from coronary heart disease for every 10% increase in persistence with statins. In Italy, a study of &gt;19&#xA0;000 patients showed that the 41% of patients with high adherence had a 40% reduction in risk of cardiovascular events, compared with those who had low adherence.<xref rid="jah31306-bib-0015" ref-type="ref">15</xref>
</p>
    </sec>
    <sec id="jah31306-sec-0004">
      <title>Persistence, Putative Adverse Effects, Health Beliefs, and Package Inserts</title>
      <p>If nonpersistence were unavoidable&#x2014;for example, if patients stopped statins for good reason or if physicians discontinued statins for good reason, such as causally related adverse effects&#x2014;there might be little reason to try to improve on it. However, there are many reasons why patients and physicians mistakenly stop these medications. There are probably only 2 important causally related adverse effects of statins&#x2014;myopathy and impairment of insulin resistance&#x2014;and as discussed later, both are probably related to impaired mitochondrial function and are treatable or avoidable in most cases. Yet, as shown in Table&#xA0;<xref rid="jah31306-tbl-0001" ref-type="table-wrap">1</xref>, adapted from a study by Zhang et&#xA0;al,<xref rid="jah31306-bib-0016" ref-type="ref">16</xref> most patients stop statins for other reasons, and most patients who stopped them because of adverse effects attributed to statins were able to continue them when rechallenged.</p>
      <table-wrap id="jah31306-tbl-0001" xml:lang="en" orientation="portrait" position="float">
        <label>Table 1</label>
        <caption>
          <p>Reasons for Discontinuation of Statins</p>
        </caption>
        <table frame="hsides" rules="groups">
          <col style="border-right:solid 1px #000000" span="1"/>
          <col style="border-right:solid 1px #000000" span="1"/>
          <thead valign="top">
            <tr style="border-bottom:solid 1px #000000">
              <th align="left" valign="top" rowspan="1" colspan="1">Reasons for Discontinuation of Statins Among Patients With a Statin&#x2010;Attributed Event</th>
              <th align="left" valign="top" rowspan="1" colspan="1">Percent of Patients</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" rowspan="1" colspan="1">No longer necessary, ineffective, change requested by insurance</td>
              <td align="left" rowspan="1" colspan="1">16</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Inadequate coverage by insurance, too expensive, switch to another drug, rejected by patient</td>
              <td align="left" rowspan="1" colspan="1">4.8</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Adverse events attributed to statins</td>
              <td align="left" rowspan="1" colspan="1">11.9</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Myalgia or myopathy</td>
              <td align="left" rowspan="1" colspan="1">4.71</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Other musculoskeletal problems (cramps, arthralgia, extremity pain, other)</td>
              <td align="left" rowspan="1" colspan="1">2.54</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:10%" rowspan="1" colspan="1">General medical (asthenia, pain fatigue, other)</td>
              <td align="left" rowspan="1" colspan="1">2.31</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hepatobiliary</td>
              <td align="left" rowspan="1" colspan="1">2.1</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Gastrointestinal</td>
              <td align="left" rowspan="1" colspan="1">1.6</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Nervous system and psychiatric disorders (memory, other)</td>
              <td align="left" rowspan="1" colspan="1">0.82</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Immune, vascular, cardiac disorders</td>
              <td align="left" rowspan="1" colspan="1">0.86</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Injury, poisoning, skin, reproductive, respiratory, thoracic, mediastinal, ear/labyrinth</td>
              <td align="left" rowspan="1" colspan="1">0.4</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Blood/lymphatic, renal/urinary, eye, metabolism/nutrition</td>
              <td align="left" rowspan="1" colspan="1">0.08</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="jah31306-note-0001">
            <p>Based on data from 107&#xA0;835 patients in routine care from Zhang et&#xA0;al.<xref rid="jah31306-bib-0016" ref-type="ref">16</xref>
</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <sec id="jah31306-sec-0005">
        <title>Why Patients Mistakenly Stop Statins</title>
        <p>One important reason for patient discontinuation of statins is that too often package inserts provide misleading information. They commonly list not just causally related adverse effects of statins but also mythical adverse effects and, in too many cases, simply all symptoms known to humankind,<xref rid="jah31306-bib-0017" ref-type="ref">17</xref> whether they were caused by the medication, cancer, a flulike illness, a hangover, or any other cause. Patients read such lists and often stop their medication when they have a symptom they find on the list. Perhaps the worst word on such lists is &#x201C;dizziness,&#x201D; a word that has so many meanings it is worse than useless. There are drugs, such as &#x3B1;&#x2010;blockers and tricyclic antidepressants, that can cause postural hypotension, but there is probably no drug that causes vertigo. Busy physicians who respond to patients' concerns by simply changing medications (rather than discussing the issue of causality) merely feed into the patients' belief that the symptoms were causally related to the drug. In some patients, this may result in long lists of drugs that &#x201C;cause&#x201D; adverse effects, most of which are not causally related. What is needed is useful information about causality&#x2014;such as a table showing the frequency of symptoms on active drug versus placebo. Such lists make it obvious that, in most cases, common symptoms such as fatigue, headache, nausea, diarrhea, constipation, and so on are just as common when taking placebo as when taking active drug.</p>
        <p>In extreme cases, it may be useful to carry out a blinded &#x201C;n&#x2010;of&#x2010;1&#x201D; crossover study to determine the likelihood of causality.<xref rid="jah31306-bib-0017" ref-type="ref">17</xref> This may seem difficult to carry out, but we have used it in clinical practice. Unfortunately, some patients convinced of causality may not accept a negative result.</p>
      </sec>
      <sec id="jah31306-sec-0006">
        <title>Why Physicians Mistakenly Discontinue Statins</title>
        <p>Reasons why physicians inappropriately discontinue or limit the dose of statins include commonly held myths about statin adverse effects including hepatotoxicity, nephrotoxicity, cognitive decline, cataracts, and intracerebral hemorrhage (ICH). In some cases, this may be driven by concern about litigation, when guidelines specify, for example, monitoring of liver function.</p>
        <p>Although rare cases of true hepatotoxicity may exist,<xref rid="jah31306-bib-0001" ref-type="ref">1</xref> statins probably do not cause hepatotoxicity, as stated in the 2013 International Atherosclerosis Society guideline.<xref rid="jah31306-bib-0018" ref-type="ref">18</xref> Fluctuations in blood levels of transaminase enzymes that are often blamed on statins (&#x201C;transaminitis&#x201D;) are more likely to be caused by fatty liver or by release of enzymes from muscle in patients with statin myopathy.<xref rid="jah31306-bib-0019" ref-type="ref">19</xref>, <xref rid="jah31306-bib-0020" ref-type="ref">20</xref> In the Heart Protection Study, in which &gt;20&#xA0;000 high&#x2010;risk patients were randomized to simvastatin 40&#xA0;mg versus placebo and were followed for 5&#xA0;years, hepatotoxicity was undetectable.<xref rid="jah31306-bib-0021" ref-type="ref">21</xref> Athyros et&#xA0;al<xref rid="jah31306-bib-0022" ref-type="ref">22</xref> compared patients with and without abnormal liver function tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study. They found that liver function tests actually improved among patients given statins, whereas they worsened in patients not given statins. Further, the cardiovascular benefit of statins was greater among patients with abnormal liver function tests than among patients with normal liver function tests at baseline. Their conclusion<xref rid="jah31306-bib-0022" ref-type="ref">22</xref> was that &#x201C;Statin treatment is safe and can improve liver tests and reduce cardiovascular morbidity in patients with mild&#x2010;to&#x2010;moderately abnormal liver tests that are potentially attributable to non&#x2010;alcoholic fatty liver disease.&#x201D; Guidelines regarding monitoring of liver function in patients taking statins should be revised accordingly.</p>
        <p>The myth of ICH from statins<xref rid="jah31306-bib-0023" ref-type="ref">23</xref> arose mainly from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial<xref rid="jah31306-bib-0024" ref-type="ref">24</xref> and resulted from intention&#x2010;to&#x2010;treat analyses that did not take into account the high rate of crossover of patients from placebo to active therapy or the high dropout rate. Patients in that study were randomized to atorvastatin 80&#xA0;mg daily versus placebo, so patients taking atorvastatin had much lower levels of LDL cholesterol. However, patients with ICH in that study did not have lower levels of LDL; a more likely interpretation of the reason for the observed increased risk of ICH is that they stopped their antihypertensive medication when they went off their study medication.<xref rid="jah31306-bib-0025" ref-type="ref">25</xref> Recent studies from a stroke registry,<xref rid="jah31306-bib-0026" ref-type="ref">26</xref> a population&#x2010;based study,<xref rid="jah31306-bib-0027" ref-type="ref">27</xref> a meta&#x2010;analysis,<xref rid="jah31306-bib-0028" ref-type="ref">28</xref> and studies in patients treated with thrombolysis<xref rid="jah31306-bib-0029" ref-type="ref">29</xref>, <xref rid="jah31306-bib-0030" ref-type="ref">30</xref>, <xref rid="jah31306-bib-0031" ref-type="ref">31</xref> confirmed that low levels of LDL cholesterol or statins do not increase the risk of ICH. Statins also probably do not cause cataracts.<xref rid="jah31306-bib-0032" ref-type="ref">32</xref>
</p>
        <p>Despite anecdotes and 2 suggestive small studies,<xref rid="jah31306-bib-0033" ref-type="ref">33</xref>, <xref rid="jah31306-bib-0034" ref-type="ref">34</xref> statins probably do not cause cognitive decline. There was no association of statins with dementia in the Cardiovascular Health Study,<xref rid="jah31306-bib-0035" ref-type="ref">35</xref> the Ginkgo Evaluation of Memory Study,<xref rid="jah31306-bib-0036" ref-type="ref">36</xref> or the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study.<xref rid="jah31306-bib-0037" ref-type="ref">37</xref> In the Rotterdam Study, statins reduced the occurrence of dementia.<xref rid="jah31306-bib-0038" ref-type="ref">38</xref> There are good reasons to think that therapies that reduce the risk of stroke should also reduce the risk of dementia.<xref rid="jah31306-bib-0039" ref-type="ref">39</xref> Indeed, a meta&#x2010;analysis showed in 2013 that statins reduced the risk of dementia.<xref rid="jah31306-bib-0040" ref-type="ref">40</xref>
</p>
        <p>There may be a difference between dementia and reversible cognitive dysfunction attributed by some patients to statin therapy; however, the burden of the evidence suggests that statins probably do not impair cognitive function.<xref rid="jah31306-bib-0041" ref-type="ref">41</xref>, <xref rid="jah31306-bib-0042" ref-type="ref">42</xref>, <xref rid="jah31306-bib-0043" ref-type="ref">43</xref>, <xref rid="jah31306-bib-0044" ref-type="ref">44</xref> While it seems unlikely that reversible cognitive impairment would be causally related to statin, a blinded n&#x2010;of&#x2010;1 crossover trial (described later) may be helpful in establishing whether a patient's complaint is truly related to statin therapy. Unfortunately, patients convinced of adverse effects that are probably not causal are extremely difficult to persuade otherwise.</p>
        <p>There is no doubt that rhabdomyolysis from statin myopathy can cause renal failure. This is particularly a problem when statins that are metabolized during absorption by intestinal cytochrome P450 (CYP)3A4 are coprescribed with drugs that inhibit that mechanism<xref rid="jah31306-bib-0045" ref-type="ref">45</xref> or, as discussed later, when patients taking such statins consume grapefruit. However, independent of rhabdomyolysis, the myth of nephrotoxicity from statins probably arose from reports of proteinuria after initiation of statins, particularly rosuvastatin.<xref rid="jah31306-bib-0046" ref-type="ref">46</xref> Such reports were based on dipstick assessment of proteinuria and were probably not caused by nephrotoxicity but rather by changes in tubular secretion of low&#x2010;molecular&#x2010;weight proteins.<xref rid="jah31306-bib-0047" ref-type="ref">47</xref> It is possible that increases in serum creatine released from damaged muscle may cause a falsely low estimated glomerular filtration rate, when calculated from serum creatinine. It is now clear that statins actually slow the decline in renal function<xref rid="jah31306-bib-0048" ref-type="ref">48</xref>, <xref rid="jah31306-bib-0049" ref-type="ref">49</xref>, <xref rid="jah31306-bib-0050" ref-type="ref">50</xref>, <xref rid="jah31306-bib-0051" ref-type="ref">51</xref> or improve renal function.<xref rid="jah31306-bib-0052" ref-type="ref">52</xref>
</p>
      </sec>
    </sec>
    <sec id="jah31306-sec-0007">
      <title>Statin Myopathy</title>
      <p>The most common causally related adverse effect of statins is myopathy. Even without myopathic symptoms, simvastatin 40&#xA0;mg daily impaired adaptation to exercise training and muscle mitochondrial content in participants with metabolic syndrome.<xref rid="jah31306-bib-0053" ref-type="ref">53</xref> In real&#x2010;world practice, myalgias and cramps are more common than estimated from clinical trials; in a cardiology clinic in the Netherlands, one&#x2010;third of patients reported such problems.<xref rid="jah31306-bib-0054" ref-type="ref">54</xref> Bruckert et&#xA0;al<xref rid="jah31306-bib-0055" ref-type="ref">55</xref> reported in a study of 7924 outpatients taking high&#x2010;dose statins that 38% had limitation of even moderate exertion by muscle pain. Rosenbaum et&#xA0;al<xref rid="jah31306-bib-0056" ref-type="ref">56</xref> reported that among 1074 patients taking statins, 62% complained of stiffness, 67% of cramps, and 50% of weakness or a loss of strength during exertion; 42% of patients had major disruption to their everyday life. However, weakness and wasting are less common (&#x2248;1%), and rhabdomyolysis is rare (&#x2248;0.1%).<xref rid="jah31306-bib-0057" ref-type="ref">57</xref>
</p>
      <sec id="jah31306-sec-0008">
        <title>Mechanisms of Statin Myopathy</title>
        <p>Vaklavas et&#xA0;al<xref rid="jah31306-bib-0058" ref-type="ref">58</xref> reviewed molecular mechanisms for statin myopathy. One possibility discussed in their review was protein modification. Statins can affect protein prenylation, an important posttranslational modification of membrane&#x2010;bound proteins, and can adversely affect synthesis of selenoprotein and dolichols, which are involved in the process of protein glycosylation.</p>
        <p>Phillips and Haas<xref rid="jah31306-bib-0059" ref-type="ref">59</xref> have argued that lipid lowering per se may cause statin myopathy, but an alternative and more likely explanation is that inhibition of HMG&#x2010;CoA reductase reduces formation of isoprenoids farnesyl pyrophosphate and geranylgeranyl pyrophosphate, resulting in reduced prenylation of small GTPase proteins involved in cell growth and maintenance<xref rid="jah31306-bib-0060" ref-type="ref">60</xref>; this also results in decreased formation of ubiquinone (Coenzyme Q10 [CoQ10]). Much of statin myopathy may be caused by depletion of muscle levels of ubiquinone (CoQ10) and resultant impairment of mitochondrial function<xref rid="jah31306-bib-0061" ref-type="ref">61</xref>, <xref rid="jah31306-bib-0062" ref-type="ref">62</xref>, <xref rid="jah31306-bib-0063" ref-type="ref">63</xref> (Figure&#xA0;<xref rid="jah31306-fig-0001" ref-type="fig">1</xref>).<xref rid="jah31306-bib-0064" ref-type="ref">64</xref> Mechanisms were reviewed by Needham and Mastaglia<xref rid="jah31306-bib-0060" ref-type="ref">60</xref> and by the European Atherosclerosis Society Consensus Panel.<xref rid="jah31306-bib-0002" ref-type="ref">2</xref> Vladutiu found that muscle levels of CoQ10 in patients with statin myopathy were 3 to 4 SDs below normal.<xref rid="jah31306-bib-0065" ref-type="ref">65</xref> This effect is directly related to potency of statins, although lipophilicity may aggravate the problem, with a theoretical advantage of the more hydrophilic rosuvastatin and pravastatin. Brewer<xref rid="jah31306-bib-0066" ref-type="ref">66</xref> reported that for a given reduction in LDL cholesterol, rosuvastatin increased plasma levels of creatine kinase less than other statins.</p>
        <fig fig-type="Figure" xml:lang="en" id="jah31306-fig-0001" orientation="portrait" position="float">
          <label>Figure 1</label>
          <caption>
            <p>Illustration of the proposed theory explaining statin myopathy as related to cellular ubiquinone depletion. Statins inhibit hydroxy&#x2010;methylglutaryl&#x2010;coenzyme A (<styled-content style="fixed-case">HMG</styled-content>&#x2010;CoA) reductase, leading to reduced production of mevalonate pathway metabolites, including ubiquinone or CoQ10. Ubiquinone is an essential coenzyme in the process of mitochondrial respiration, facilitating the transfer of electrons between complex I and <styled-content style="fixed-case">II</styled-content> of the respiratory chain. Consequently, depletion of ubiquinone may impair mitochondrial respiration and cellular energy production within skeletal muscle. <styled-content style="fixed-case">ADP</styled-content> indicates adenosine diphosphate; <styled-content style="fixed-case">ATP</styled-content>, adenosine triphosphate; <styled-content style="fixed-case">NAD</styled-content>1, nicotinamide adenine dinucleotide (reduced form); <styled-content style="fixed-case">NADH</styled-content>, nicotinamide adenine dinucleotide (oxidized form); P, phosphate. Reproduced by permission of the publisher from Parker et&#xA0;al.<xref rid="jah31306-bib-0064" ref-type="ref">64</xref>
</p>
          </caption>
          <graphic id="nlm-graphic-1" xlink:href="JAH3-5-e002497-g001"/>
        </fig>
      </sec>
    </sec>
    <sec id="jah31306-sec-0009">
      <title>Factors That Increase Adverse Effects by Increasing Exposure to Statins</title>
      <p>There are a number of mechanisms that affect drug exposure in individual patients; these are integral to and associated with risk of adverse events that exhibit dose dependence (notably myopathy). They include pharmacokinetic interactions, and pharmacogenomic factors that result in higher levels of statins in the blood and in hepatic and muscle tissue.</p>
    </sec>
    <sec id="jah31306-sec-0010">
      <title>Pharmacokinetic Interactions</title>
      <sec id="jah31306-sec-0011">
        <title>Drugs</title>
        <p>Two main classes of drug interactions will account for most of the important interactions of statins with other drugs: drugs that affect CYP3A4/5 and drugs that affect transport proteins. An additional mechanism, affected by gemfibrozil, is glucuronidation.<xref rid="jah31306-bib-0067" ref-type="ref">67</xref> Tables&#xA0;<xref rid="jah31306-tbl-0002" ref-type="table-wrap">2</xref> and <xref rid="jah31306-tbl-0003" ref-type="table-wrap">3</xref> summarize statin metabolism and interactions.<xref rid="jah31306-bib-0068" ref-type="ref">68</xref>, <xref rid="jah31306-bib-0069" ref-type="ref">69</xref>, <xref rid="jah31306-bib-0070" ref-type="ref">70</xref>, <xref rid="jah31306-bib-0071" ref-type="ref">71</xref>, <xref rid="jah31306-bib-0072" ref-type="ref">72</xref>, <xref rid="jah31306-bib-0073" ref-type="ref">73</xref>, <xref rid="jah31306-bib-0074" ref-type="ref">74</xref>, <xref rid="jah31306-bib-0075" ref-type="ref">75</xref> For reasons discussed later, simvastatin and lovastatin are particularly susceptible to huge drug interactions. Indeed, in considering the clinical relevance of polymorphisms of <italic>SLCO1B1</italic> affecting statins, the Clinical Pharmacogenomics Implementation Consortium restricted its concerns to simvastatin.<xref rid="jah31306-bib-0067" ref-type="ref">67</xref>
</p>
        <table-wrap id="jah31306-tbl-0002" xml:lang="en" orientation="portrait" position="float">
          <label>Table 2</label>
          <caption>
            <p>Summary of Relevant Pharmacokinetic Determinants of Disposition for Selected HMG&#x2010;CoA Reductase Inhibitors<xref rid="jah31306-bib-0068" ref-type="ref">68</xref>, <xref rid="jah31306-bib-0069" ref-type="ref">69</xref>, <xref rid="jah31306-bib-0070" ref-type="ref">70</xref>, <xref rid="jah31306-bib-0071" ref-type="ref">71</xref>, <xref rid="jah31306-bib-0072" ref-type="ref">72</xref>, <xref rid="jah31306-bib-0073" ref-type="ref">73</xref>, <xref rid="jah31306-bib-0074" ref-type="ref">74</xref>, <xref rid="jah31306-bib-0075" ref-type="ref">75</xref>
</p>
          </caption>
          <table frame="hsides" rules="groups">
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <thead valign="top">
              <tr style="border-bottom:solid 1px #000000">
                <th align="left" valign="top" rowspan="1" colspan="1"/>
                <th align="left" valign="top" rowspan="1" colspan="1">Oral Bioavailability</th>
                <th align="left" valign="top" rowspan="1" colspan="1">Metabolism</th>
                <th align="left" valign="top" rowspan="1" colspan="1">Transport</th>
                <th align="left" valign="top" rowspan="1" colspan="1">Effect of SLCO1B1 Variants on Drug Exposure</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" rowspan="1" colspan="1">Atorvastatin</td>
                <td align="left" rowspan="1" colspan="1">12&#x2013;14%</td>
                <td align="left" rowspan="1" colspan="1">CYP3A4/5</td>
                <td align="left" rowspan="1" colspan="1">ABCB1, ABCC2, SLCO1B1</td>
                <td align="left" rowspan="1" colspan="1">&#x2191;52&#x2013;144%</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Fluvastatin</td>
                <td align="left" rowspan="1" colspan="1">19&#x2013;29%</td>
                <td align="left" rowspan="1" colspan="1">CYP2C8/9/19</td>
                <td align="left" rowspan="1" colspan="1">SLCO1B1, SLC15A1</td>
                <td align="left" rowspan="1" colspan="1">&#x2191;13&#x2013;19% (NS)</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Lovastatin</td>
                <td align="left" rowspan="1" colspan="1">&lt;5%</td>
                <td align="left" rowspan="1" colspan="1">CYP3A4/5</td>
                <td align="left" rowspan="1" colspan="1">ABCB1, ABCC2, SLCO1B1</td>
                <td align="left" rowspan="1" colspan="1">NA</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Pravastatin</td>
                <td align="left" rowspan="1" colspan="1">18%</td>
                <td align="left" rowspan="1" colspan="1">Sulfation</td>
                <td align="left" rowspan="1" colspan="1">SLCO2B1, SLCO1B1, ABCB1/11, ABCG2, ABCC2, SLC22A6/8</td>
                <td align="left" rowspan="1" colspan="1">&#x2191;39&#x2013;111%</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Rosuvastatin</td>
                <td align="left" rowspan="1" colspan="1">20%</td>
                <td align="left" rowspan="1" colspan="1">CYP2C9,2C19</td>
                <td align="left" rowspan="1" colspan="1">ABCB11, SLCO1B1, SLCO2B1</td>
                <td align="left" rowspan="1" colspan="1">&#x2191;6&#x2013;117%</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Simvastatin</td>
                <td align="left" rowspan="1" colspan="1">&lt;5%</td>
                <td align="left" rowspan="1" colspan="1">CYP3A4/5</td>
                <td align="left" rowspan="1" colspan="1">ABCB1, ABCC2, SLCO1B1</td>
                <td align="left" rowspan="1" colspan="1">&#x2191;23&#x2013;221%</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <table-wrap id="jah31306-tbl-0003" xml:lang="en" orientation="portrait" position="float">
          <label>Table 3</label>
          <caption>
            <p>Major Pharmacokinetic Interactions and Magnitude of Effect<xref rid="jah31306-bib-0068" ref-type="ref">68</xref>, <xref rid="jah31306-bib-0069" ref-type="ref">69</xref>, <xref rid="jah31306-bib-0070" ref-type="ref">70</xref>, <xref rid="jah31306-bib-0071" ref-type="ref">71</xref>, <xref rid="jah31306-bib-0072" ref-type="ref">72</xref>, <xref rid="jah31306-bib-0073" ref-type="ref">73</xref>, <xref rid="jah31306-bib-0074" ref-type="ref">74</xref>, <xref rid="jah31306-bib-0075" ref-type="ref">75</xref>
</p>
          </caption>
          <table frame="hsides" rules="groups">
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <thead valign="top">
              <tr style="border-bottom:solid 1px #000000">
                <th align="left" valign="top" rowspan="1" colspan="1">Disposition Pathway</th>
                <th align="left" valign="top" rowspan="1" colspan="1">HMG&#x2010;CoA Reductase Inhibitor</th>
                <th align="left" valign="top" rowspan="1" colspan="1">Reported Change in Area Under the Curve With Interacting Agent</th>
                <th align="left" valign="top" rowspan="1" colspan="1">Important Interacting Agents</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" rowspan="3" colspan="1">CYP3A4/5&#xB1;OATP1B1</td>
                <td align="left" rowspan="1" colspan="1">Atorvastatin</td>
                <td align="left" rowspan="1" colspan="1">+50% to 500%</td>
                <td align="left" rowspan="3" colspan="1">Amiodarone, clarithromycin, diltiazem, grapefruit juice, itraconazole, ketoconazole, protease inhibitors</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Lovastatin</td>
                <td align="left" rowspan="1" colspan="1">+200% to 2000%</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Simvastatin</td>
                <td align="left" rowspan="1" colspan="1">+200% to 2000%</td>
              </tr>
              <tr>
                <td align="left" rowspan="2" colspan="1">CYP2C8/9/19</td>
                <td align="left" rowspan="1" colspan="1">Fluvastatin</td>
                <td align="left" rowspan="1" colspan="1">+84% to 400%</td>
                <td align="left" rowspan="2" colspan="1">Cyclosporine, fluconazole</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Rosuvastatin</td>
                <td align="left" rowspan="1" colspan="1">NS</td>
              </tr>
              <tr>
                <td align="left" rowspan="5" colspan="1">OATP1B1</td>
                <td align="left" rowspan="1" colspan="1">Atorvastatin</td>
                <td align="left" rowspan="1" colspan="1">Minimal</td>
                <td align="left" rowspan="5" colspan="1">Gemfibrozil</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Lovastatin</td>
                <td align="left" rowspan="1" colspan="1">+100% to 200%</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Simvastatin</td>
                <td align="left" rowspan="1" colspan="1">+100% to 200%</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Pravastatin</td>
                <td align="left" rowspan="1" colspan="1">+100%</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Rosuvastatin</td>
                <td align="left" rowspan="1" colspan="1">+100%</td>
              </tr>
              <tr>
                <td align="left" rowspan="6" colspan="1">MDR1+OATP1B1+other transporters</td>
                <td align="left" rowspan="1" colspan="1">Atorvastatin</td>
                <td align="left" rowspan="1" colspan="1">+500% to 1400%</td>
                <td align="left" rowspan="6" colspan="1">Cyclosporine</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Fluvastatin</td>
                <td align="left" rowspan="1" colspan="1">+100% to 300%</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Lovastatin</td>
                <td align="left" rowspan="1" colspan="1">+400% to 2000%</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Pravastatin</td>
                <td align="left" rowspan="1" colspan="1">+400% to 1000%</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Rosuvastatin</td>
                <td align="left" rowspan="1" colspan="1">+400% to 1000%</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Simvastatin</td>
                <td align="left" rowspan="1" colspan="1">+500% to 700%</td>
              </tr>
              <tr>
                <td align="left" rowspan="6" colspan="1">Inducers of CYP3A4+MDR1&#xB1;other transporters</td>
                <td align="left" rowspan="1" colspan="1">Atorvastatin</td>
                <td align="left" rowspan="1" colspan="1">&#x2212;60% to 90%</td>
                <td align="left" rowspan="6" colspan="1">Rifampin, carbamazepine</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Fluvastatin</td>
                <td align="left" rowspan="1" colspan="1">&#x2212;50%</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Lovastatin</td>
                <td align="left" rowspan="1" colspan="1">NA</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Pravastatin</td>
                <td align="left" rowspan="1" colspan="1">&#x2212;30%</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Rosuvastatin</td>
                <td align="left" rowspan="1" colspan="1">NS</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Simvastatin</td>
                <td align="left" rowspan="1" colspan="1">&#x2212;70% to 95%</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
    </sec>
    <sec id="jah31306-sec-0012">
      <title>Grapefruit Juice</title>
      <p>The effect of grapefruit on drug metabolism was first described by our group in 1989<xref rid="jah31306-bib-0076" ref-type="ref">76</xref> and further elucidated in 1991.<xref rid="jah31306-bib-0077" ref-type="ref">77</xref> The discovery was serendipitous; we used grapefruit to mask the flavor of ethanol in a study of interaction between ethanol and felodipine.<xref rid="jah31306-bib-0076" ref-type="ref">76</xref>, <xref rid="jah31306-bib-0078" ref-type="ref">78</xref> Almost immediately, drug manufacturers sought to downplay the magnitude and importance of this interaction, and this may possibly account for the important underestimation of this problem. Contrary to the statement by Egan and Colman,<xref rid="jah31306-bib-0079" ref-type="ref">79</xref> large quantities of grapefruit are not required to have an important effect on drug metabolism. Grapefruit juice, probably mainly through the effect of cyanocoumarins, is a suicide inhibitor of gut wall CYP3A4; only a single glass of grapefruit juice<xref rid="jah31306-bib-0080" ref-type="ref">80</xref> or a single fruit daily<xref rid="jah31306-bib-0081" ref-type="ref">81</xref> is required to have the effect, and it persists for &gt;24&#xA0;hours, so it is not safe to take the drug in the evening if the grapefruit is taken in the morning, as is so often stated. This is a particular problem with drugs that have low bioavailability caused by inactivation during absorption by intestinal CYP3A4. Because simvastatin and lovastatin are only 5% bioavailable as a result of this mechanism, grapefruit and other inhibitors of CYP3A4 have the theoretical potential to increase blood levels 20&#x2010;fold, and indeed grapefruit increases the area under the curve of the levels of both simvastatin<xref rid="jah31306-bib-0080" ref-type="ref">80</xref> and lovastatin<xref rid="jah31306-bib-0082" ref-type="ref">82</xref> by 15&#x2010;fold. Atorvastatin area under the curve only doubles with grapefruit,<xref rid="jah31306-bib-0083" ref-type="ref">83</xref> and pravastatin and rosuvastatin are not affected.<xref rid="jah31306-bib-0083" ref-type="ref">83</xref>, <xref rid="jah31306-bib-0084" ref-type="ref">84</xref>
</p>
      <p>Although pharmacists will often detect potential drug interactions, grocers seldom inquire about medication history when dispensing grapefruit.<xref rid="jah31306-bib-0085" ref-type="ref">85</xref> For this reason, a case report from Germany illustrates why particular caution is needed with simvastatin and lovastatin. A woman taking 80&#xA0;mg of simvastatin daily developed rhabdomyolysis 4&#xA0;days after beginning to consume one grapefruit daily.<xref rid="jah31306-bib-0081" ref-type="ref">81</xref>
</p>
    </sec>
    <sec id="jah31306-sec-0013">
      <title>Insulin Resistance/Aggravation of Diabetes</title>
      <p>In the past several years, it has become evident that statins increase the risk of incident diabetes, by &#x2248;9% to 28%.<xref rid="jah31306-bib-0086" ref-type="ref">86</xref>, <xref rid="jah31306-bib-0087" ref-type="ref">87</xref>, <xref rid="jah31306-bib-0088" ref-type="ref">88</xref>, <xref rid="jah31306-bib-0089" ref-type="ref">89</xref> For this reason, among others, we tend to use low&#x2010;moderate doses of statins in combination with ezetimibe. Because statins and ezetimibe affect different mechanisms, they are synergistic: 10&#xA0;mg of atorvastatin with 10&#xA0;mg of ezetimibe lowers the LDL to the same extent as 80&#xA0;mg of atorvastatin<xref rid="jah31306-bib-0090" ref-type="ref">90</xref> but, in our experience, with fewer adverse effects. It seems likely from meta&#x2010;analyses that most of the benefit of statins is the result of the reduction in LDL cholesterol.<xref rid="jah31306-bib-0091" ref-type="ref">91</xref> Putative benefits such as lowering of C&#x2010;reactive protein are unlikely to be important, since Mendelian randomization studies<xref rid="jah31306-bib-0092" ref-type="ref">92</xref>, <xref rid="jah31306-bib-0093" ref-type="ref">93</xref> and some large clinical trials<xref rid="jah31306-bib-0094" ref-type="ref">94</xref>, <xref rid="jah31306-bib-0095" ref-type="ref">95</xref> indicate that lowering of C&#x2010;reactive protein is probably not important in vascular prevention. The results of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE&#x2010;IT) trial<xref rid="jah31306-bib-0096" ref-type="ref">96</xref> support this approach.</p>
      <p>Despite the increase in incident diabetes, the cardiovascular risk reduction with statins is of similar magnitude in diabetics to that in nondiabetics,<xref rid="jah31306-bib-0087" ref-type="ref">87</xref>, <xref rid="jah31306-bib-0088" ref-type="ref">88</xref> and because diabetics are at high risk of cardiovascular events, they should be treated with statins.<xref rid="jah31306-bib-0097" ref-type="ref">97</xref> What is less well known is that supplementation with <sc>l</sc>&#x2010;carnitine can prevent the adverse effects of statins on diabetes<xref rid="jah31306-bib-0098" ref-type="ref">98</xref>, <xref rid="jah31306-bib-0099" ref-type="ref">99</xref> and insulin resistance.<xref rid="jah31306-bib-0100" ref-type="ref">100</xref> Further, in diabetics taking statins, supplementation with <sc>l</sc>&#x2010;carnitine improves the effect of the statin on LDL cholesterol, high&#x2010;density lipoprotein cholesterol, lipoprotein(a), and LDL particle size.<xref rid="jah31306-bib-0098" ref-type="ref">98</xref>
<sc>l</sc>&#x2010;Carnitine is required for entry of fatty acids into mitochondria and thus has a central role in energy metabolism and mitochondrial function.<xref rid="jah31306-bib-0101" ref-type="ref">101</xref> All of the foregoing therefore supports the hypothesis that the adverse effects of statins may be largely caused by mitochondrial dysfunction.</p>
    </sec>
    <sec id="jah31306-sec-0014">
      <title>Genetic Predisposition</title>
      <p>It is likely that patients who develop statin myopathy are predisposed genetically.<xref rid="jah31306-bib-0062" ref-type="ref">62</xref>, <xref rid="jah31306-bib-0065" ref-type="ref">65</xref>, <xref rid="jah31306-bib-0102" ref-type="ref">102</xref> There appear to be 2 main mechanisms by which patients may be genetically predisposed to statin myopathy. One is pharmacogenomic&#x2014;mutations affecting absorption, metabolism, transport, and removal of statins that result in higher blood levels and higher tissue levels of statins.<xref rid="jah31306-bib-0084" ref-type="ref">84</xref> Another is mutations affecting mitochondrial function<xref rid="jah31306-bib-0062" ref-type="ref">62</xref>, <xref rid="jah31306-bib-0065" ref-type="ref">65</xref>, <xref rid="jah31306-bib-0102" ref-type="ref">102</xref>; the latter could affect either mitochondrial genes<xref rid="jah31306-bib-0103" ref-type="ref">103</xref> or somatic genes affecting mitochondrial function.<xref rid="jah31306-bib-0104" ref-type="ref">104</xref> A third category is disorders of muscle metabolism independent of mitochondrial function, including a polymorphism of glycine amidinotransferase that encodes the rate&#x2010;limiting enzyme in creatine synthesis.<xref rid="jah31306-bib-0105" ref-type="ref">105</xref> Other mechanisms include genetic variants affecting glucose metabolism, synthesis of CoQ10, lactic acid metabolism, and sensitivity to pain. Table&#xA0;<xref rid="jah31306-tbl-0004" ref-type="table-wrap">4</xref>, <xref rid="jah31306-bib-0065" ref-type="ref">65</xref>, <xref rid="jah31306-bib-0102" ref-type="ref">102</xref>, <xref rid="jah31306-bib-0106" ref-type="ref">106</xref> summarizes the genes involved.</p>
      <table-wrap id="jah31306-tbl-0004" xml:lang="en" orientation="portrait" position="float">
        <label>Table 4</label>
        <caption>
          <p>Genetic Predisposition to Statin Adverse Effects<xref rid="jah31306-bib-0065" ref-type="ref">65</xref>, <xref rid="jah31306-bib-0102" ref-type="ref">102</xref>, <xref rid="jah31306-bib-0106" ref-type="ref">106</xref>
</p>
        </caption>
        <table frame="hsides" rules="groups">
          <col style="border-right:solid 1px #000000" span="1"/>
          <tbody>
            <tr>
              <td align="left" rowspan="1" colspan="1">Pharmacogenomic mechanisms that increase blood and tissue levels of statins</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Absorption</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:15%" rowspan="1" colspan="1">SCLO1B1, which encodes organic anion transport protein B1 (OATPB1)</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Metabolism (cytochrome P450, subfamily genes)</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:15%" rowspan="1" colspan="1">CYP2C8</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:15%" rowspan="1" colspan="1">CYP2D6</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Intestinal wall first&#x2010;pass metabolism (during absorption)</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:15%" rowspan="1" colspan="1">CYP3A4/5</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Distribution (tissue levels of drug in muscle)</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Uptake transporters</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:20%" rowspan="1" colspan="1">OATP2B1 (human organic anion transporting polypeptide 2B1)</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Efflux transporters</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Multidrug resistance&#x2013;associated proteins (ATP binding cassette subfamily C genes)</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:10%" rowspan="1" colspan="1">ABCC1 (MRP1)</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:10%" rowspan="1" colspan="1">ABCC4 (MRP4)</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:10%" rowspan="1" colspan="1">ABCC5 (MRP5)</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Mitochondrial dysfunction</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:10%" rowspan="1" colspan="1">COQ2&#x2014;CoQ10 deficiency</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:10%" rowspan="1" colspan="1">CPT2 carnitine&#x2010;palmitoyl transferase deficiency II</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Other mechanisms affecting muscle function</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:10%" rowspan="1" colspan="1">
<italic>ATP2B1</italic>&#x2014;calcium&#x2010;transporting ATPase</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:10%" rowspan="1" colspan="1">DMPK&#x2014;encodes plasma membrane calcium&#x2010;transporting ATPase 1</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:10%" rowspan="1" colspan="1">PYGM&#x2014;glycogen phosphorylase, muscle</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:10%" rowspan="1" colspan="1">AMPD1&#x2014;adenosine monophosphate deaminase 1</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:10%" rowspan="1" colspan="1">SLC16A4&#x2014;lactic acid (monocarboxylic acid) transporter</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:10%" rowspan="1" colspan="1">GATM&#x2014;glycine amidinotransferase creatine synthesis</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Other mechanisms</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:10%" rowspan="1" colspan="1">AGTR1&#x2014;angiotensin receptor 1</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:10%" rowspan="1" colspan="1">NOS3&#x2014;nitric oxide synthase 3</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:10%" rowspan="1" colspan="1">HTR3B&#x2014;5&#x2010;hydroxytryptamine receptor 3b (individual variations in pain perception)</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:10%" rowspan="1" colspan="1">HTR7&#x2014;5&#x2010;hydroxytryptamine receptor 7 (individual variations in pain perception)</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:10%" rowspan="1" colspan="1">APOE&#x2014;apolipoprotein E (reduced compliance in E4 carriers)</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>In the pharmacogenomic category, a polymorphism of SCLO1B1, which encodes organic anion transport protein B1, was shown to be associated with statin myopathy in a genome&#x2010;wide association study.<xref rid="jah31306-bib-0107" ref-type="ref">107</xref> Because several statins are metabolized to inactive forms during absorption in the intestinal wall by CYP3A4, as discussed later, it can be expected that polymorphisms or copy number variants of CYP3A4 might also affect blood levels of statins. With regard to tissue levels of drugs, and in particular muscle levels of statins, Knauer et&#xA0;al<xref rid="jah31306-bib-0108" ref-type="ref">108</xref> found that the uptake transporter human organic anion transporting polypeptide 2B1 and the efflux transporters, multidrug resistance&#x2013;associated protein 1, 4, and 5, are expressed on the sarcolemmal membrane of human skeletal muscle fibers and that atorvastatin and rosuvastatin are substrates of these transporters. Thus, variants of these transport proteins might also predispose to statin myopathy.</p>
    </sec>
    <sec id="jah31306-sec-0015">
      <title>Approaches to Minimizing Adverse Effects of Statins</title>
      <p>The main causally related adverse effects of statins, myopathy and aggravation of insulin resistance, can be minimized by several maneuvers. First, in patients who experience myopathic symptoms and in patients with insulin resistance and/or diabetes, it may be useful to limit or reduce the dose of statin, with the addition of ezetimibe, bile acid sequestrants, niacin, and/or fibrates, to maintain the LDL&#x2010;lowering effect. Ezetimibe, which blocks absorption of cholesterol at the intestinal lining, is synergistic with statins. Concerns about possible adverse effects of ezetimibe on atherosclerosis were probably misplaced and were based on measurement of carotid intima&#x2010;media thickness, which is not atherosclerosis.<xref rid="jah31306-bib-0109" ref-type="ref">109</xref>, <xref rid="jah31306-bib-0110" ref-type="ref">110</xref>, <xref rid="jah31306-bib-0111" ref-type="ref">111</xref> The IMPROVE&#x2010;IT<xref rid="jah31306-bib-0096" ref-type="ref">96</xref> showed a reduction of cardiovascular events with ezetimibe among patients with acute coronary syndromes, and the Plaque Regression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by Intravascular Ultrasound (PRECISE&#x2010;IVUS)<xref rid="jah31306-bib-0112" ref-type="ref">112</xref> showed regression of coronary plaque with ezetimibe added to atorvastatin.</p>
    </sec>
    <sec id="jah31306-sec-0016">
      <title>Possible Treatments Worth Considering</title>
      <p>It may useful to give supplements of CoQ10.<xref rid="jah31306-bib-0001" ref-type="ref">1</xref>, <xref rid="jah31306-bib-0113" ref-type="ref">113</xref> However, the doses required may need to be higher than in most of the clinical trials (200&#x2013;400&#xA0;mg twice a day, or perhaps more), as illustrated in the case report that follows. Although it is commonly stated that the effects of CoQ10 supplementation are contradictory and unproved<xref rid="jah31306-bib-0114" ref-type="ref">114</xref> and a meta&#x2010;analysis indicated that it is not beneficial,<xref rid="jah31306-bib-0115" ref-type="ref">115</xref> the authors of the meta&#x2010;analysis concluded that &#x201C;Larger, well&#x2010;designed trials are necessary to confirm the findings from this meta&#x2010;analysis.&#x201D; There may be problems with small trials, including patients who do not have true statin myopathy. A related meta&#x2010;analysis<xref rid="jah31306-bib-0116" ref-type="ref">116</xref> concluded that statins do lower levels of CoQ10 in plasma.</p>
      <p>Higher doses of ubiquinone such as 300 mg twice daily are more effective in improving muscle fatigue.<xref rid="jah31306-bib-0117" ref-type="ref">117</xref>, <xref rid="jah31306-bib-0118" ref-type="ref">118</xref> The negative trial of Bookstaver et&#xA0;al<xref rid="jah31306-bib-0119" ref-type="ref">119</xref> used only 60&#xA0;mg twice daily. Fedacko et&#xA0;al<xref rid="jah31306-bib-0120" ref-type="ref">120</xref> found a significant improvement of statin myopathy with CoQ10 200&#xA0;mg daily in a factorial designed trial in which selenium was not efficacious. Ubiquinone does improve mitochondrial function in an animal model of statin myopathy.<xref rid="jah31306-bib-0121" ref-type="ref">121</xref>
</p>
      <p>It may also be useful to add supplements of <sc>l</sc>&#x2010;carnitine (500&#x2013;1000&#xA0;mg twice a day).<xref rid="jah31306-bib-0122" ref-type="ref">122</xref>, <xref rid="jah31306-bib-0123" ref-type="ref">123</xref> In diabetics taking simvastatin, <sc>l</sc>&#x2010;carnitine not only prevented the rise of blood sugar but improved the effect of statin on LDL cholesterol, high&#x2010;density lipoprotein cholesterol, lipoprotein(a), and LDL particle size.<xref rid="jah31306-bib-0098" ref-type="ref">98</xref>, <xref rid="jah31306-bib-0099" ref-type="ref">99</xref>
<sc>l</sc>&#x2010;Carnitine was effective in an animal model of statin myopathy.<xref rid="jah31306-bib-0124" ref-type="ref">124</xref> However, effects of <sc>l</sc>&#x2010;carnitine on production of trimethylamine&#x2010;N&#x2010;oxide by intestinal bacteria<xref rid="jah31306-bib-0125" ref-type="ref">125</xref> may limit the usefulness of <sc>l</sc>&#x2010;carnitine supplements for this purpose; this will require further study. The issues have recently been reviewed.<xref rid="jah31306-bib-0126" ref-type="ref">126</xref> Table&#xA0;<xref rid="jah31306-tbl-0005" ref-type="table-wrap">5</xref> summarizes approaches to minimizing adverse effects of statins.</p>
      <table-wrap id="jah31306-tbl-0005" xml:lang="en" orientation="portrait" position="float">
        <label>Table 5</label>
        <caption>
          <p>Approaches to Minimizing Adverse Effects of Statins</p>
        </caption>
        <table frame="hsides" rules="groups">
          <col style="border-right:solid 1px #000000" span="1"/>
          <tbody>
            <tr>
              <td align="left" rowspan="1" colspan="1">For the present</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:10%" rowspan="1" colspan="1">1 Reduce the dose of statin, alternate daily dosing of statin, or switch to weaker statin</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:10%" rowspan="1" colspan="1">2 Add ezetimibe, bile acid sequestrants, niacin, fibrates, proprotein convertase subtilisin/kexin 9 antagonists/antibodies</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Possible treatments worth considering</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:10%" rowspan="1" colspan="1">1 Supplement with Coenzyme Q10 200 to 400&#xA0;mg twice daily</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:10%" rowspan="1" colspan="1">2 Supplement with <sc>l</sc>&#x2010;carnitine 500 to 1000&#xA0;mg twice daily</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">In future</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:10%" rowspan="1" colspan="1">1 Squalene synthase inhibitors?</td>
            </tr>
            <tr>
              <td align="left" style="padding-left:10%" rowspan="1" colspan="1">2 Other new therapies in development</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
    <sec id="jah31306-sec-0017">
      <title>Switching Statins, Low&#x2010;Dose and/or Alternate&#x2010;Day Statins</title>
      <p>The truly causal adverse effects of statins are probably related to efficacy in inhibition of HMG&#x2010;CoA reductase and therefore entirely attributable to intensity of statin therapy. Switching statins probably will not help reduce adverse effects except when weaker statins or lower doses of statins are used. A useful maneuver may be alternate&#x2010;day low&#x2010;dose statin in combination with ezetimibe. A case report illustrates this.</p>
    </sec>
    <sec id="jah31306-sec-0018">
      <title>Case Report</title>
      <p>The patient was a 63&#x2010;year&#x2010;old physician with a mitochondrial disorder (multiple lipomatosis) and moderately severe statin myopathy. He had severe nocturnal leg cramps that abated during drug holidays from statins and recurred reproducibly on reinitiation of statins; they were only partly relieved with CoQ10 150 mg daily. He had proximal muscle weakness in the hip girdle, and creatine kinase levels were repeatedly elevated to 4 to 5 times the upper normal limit for the laboratory, despite reducing his dose of rosuvastatin to 5&#xA0;mg daily in combination with ezetimibe. Because of these difficulties, he stopped statin therapy despite a coronary calcium score of 300 and a family history of premature cardiovascular death. At that time, his carotid total plaque area (a strong predictor of cardiovascular risk<xref rid="jah31306-bib-0127" ref-type="ref">127</xref>, <xref rid="jah31306-bib-0128" ref-type="ref">128</xref>, <xref rid="jah31306-bib-0129" ref-type="ref">129</xref>) was only 20&#xA0;mm<sup>2</sup>, so he felt somewhat reassured about the safety of stopping statin, while continuing ezetimibe. However, by April 2009, his plaque area had progressed to 29&#xA0;mm<sup>2</sup>, a matter of concern since Spence et&#xA0;al reported in 2002<xref rid="jah31306-bib-0127" ref-type="ref">127</xref> that plaque progression was associated with a doubling of risk. (This was the basis for developing a new approach to managing atherosclerosis, &#x201C;treating arteries instead of treating risk factors,&#x201D;<xref rid="jah31306-bib-0130" ref-type="ref">130</xref> which markedly reduced risk among high&#x2010;risk patients.<xref rid="jah31306-bib-0131" ref-type="ref">131</xref>) Because of the plaque progression, he began taking rosuvastatin 5&#xA0;mg on alternate days with an increased dose of CoQ10 (200&#xA0;mg daily). As shown in Figure&#xA0;<xref rid="jah31306-fig-0002" ref-type="fig">2</xref>,<xref rid="jah31306-bib-0130" ref-type="ref">130</xref> the plaque area regressed in just over 3&#xA0;months to 19&#xA0;mm<sup>2</sup>. In later years he continued ezetimibe 10&#xA0;mg daily and a Mediterranean diet, but his myopathic symptoms and high creatine kinase levels persisted. He therefore reduced the dose of rosuvastatin to 2.5&#xA0;mg on alternate days, and increased the dose of CoQ10 to 400&#xA0;mg twice daily to tolerate it, but the plaque regression persisted; in August 2015, the plaque area was only 15&#xA0;mm<sup>2</sup>.</p>
      <fig fig-type="Figure" xml:lang="en" id="jah31306-fig-0002" orientation="portrait" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Plaque regression with alternate&#x2010;day statin and daily ezetimibe. A, A soft plaque is shown at the origin of the left external carotid in a 63&#x2010;year&#x2010;old man using ezetimibe alone, having stopped statin because of statin myopathy. His plaque area had progressed from 20&#xA0;mm<sup>2</sup> 6&#xA0;months earlier, to 28&#xA0;mm<sup>2</sup>. B, After adding back rosuvastatin 5&#xA0;mg daily with CoQ10 200&#xA0;mg daily to prevent myalgias, the plaque area regressed to 0.19&#xA0;mm<sup>2</sup> in just over 3&#xA0;months. The plaque had also become denser, with regression of the soft plaque and more calcification. Reproduced by permission of the publisher from Spence and Hackam.<xref rid="jah31306-bib-0130" ref-type="ref">130</xref>
</p>
        </caption>
        <graphic id="nlm-graphic-3" xlink:href="JAH3-5-e002497-g002"/>
      </fig>
    </sec>
    <sec id="jah31306-sec-0019">
      <title>What Is to Be Done With Patients Who Are Entirely Intolerant of Statins?</title>
      <p>Some patients, particularly those with mitochondrial disorders, are entirely unable to tolerate even small doses of statins. For such patients, continuation of ezetimibe, addition of fibrates, perhaps slow&#x2010;release niacin preparations if tolerated, and strict adherence to a Mediterranean or perhaps vegan diet may be indicated.</p>
      <p>Antibodies to proprotein convertase subtilisin/kexin 9<xref rid="jah31306-bib-0132" ref-type="ref">132</xref> are recently available on the market, and offer a substitute or add&#x2010;on to low&#x2010;dose statins for patients with myopathy or diabetes. Unfortunately, their high cost may limit their usefulness.<xref rid="jah31306-bib-0133" ref-type="ref">133</xref>
</p>
      <p>In the future, the problem of statin adverse effects may be solved by the availability of new alternatives such as inhibitors of cholesterol ester transfer protein<xref rid="jah31306-bib-0134" ref-type="ref">134</xref> or siRNA silencing<xref rid="jah31306-bib-0135" ref-type="ref">135</xref> or other approaches to blocking proprotein convertase subtilisin/kexin 9, and other new therapies in development.<xref rid="jah31306-bib-0136" ref-type="ref">136</xref>, <xref rid="jah31306-bib-0137" ref-type="ref">137</xref>, <xref rid="jah31306-bib-0138" ref-type="ref">138</xref> Inhibitors of squalene synthase<xref rid="jah31306-bib-0139" ref-type="ref">139</xref> should increase levels of CoQ10 by shunting, but it appears that this class of drug may not reach the market.</p>
    </sec>
    <sec id="jah31306-sec-0020">
      <title>Conclusion</title>
      <p>Poor persistence with statin therapy is an important and common problem that can be mitigated. Many common reasons for stopping statins are invalid. Pharmacists need to provide better information to patients receiving statins, and physicians need to be better able to help their high&#x2010;risk patients persist with therapy.</p>
      <p>The main causally related adverse effect of statins is impaired insulin resistance, with a risk of diabetes and myopathy. Both of these problems are probably largely caused by impaired mitochondrial function, from depletion of ubiquinone. Although new therapies to lower LDL cholesterol are in development, statins will still be needed for some time, and statin adverse effects can be minimized by several maneuvers.</p>
    </sec>
    <sec id="jah31306-sec-0021">
      <title>Author Contributions</title>
      <p>Dr Spence wrote the initial draft of the manuscript; both authors contributed to revisions.</p>
    </sec>
    <sec id="jah31306-sec-0022">
      <title>Disclosures</title>
      <p>Dr Spence has received grants from the Canadian Institutes for Health Research, the Heart &amp; Stroke Foundation of Canada, and NIH/NINDS; lecture honoraria/travel support/consulting fees from Sanofi, Bayer, Merck, and Boehringer&#x2010;Ingelheim; research support for investigator&#x2010;initiated projects from Pfizer (substantial&#x2014;donation in kind of eplerenone and matching placebo to support a grant from the Canadian Heart &amp; Stroke Foundation for a clinical trial) and Merck (minor&#x2014;support for a summer student). During the past 30&#xA0;years, he has performed contract research with many pharma/device companies: all of the above, plus Takeda, BMS, Servier, Wyeth, Miles, Roussel, NMT, AGA, and Gore. He is an officer and shareholder of Vascularis Inc. He is a member of the editorial boards of <italic>Hypertension</italic>,<italic> Stroke</italic>, and <italic>Arteriosclerosis, Thrombosis and Vascular Biology</italic> and receives royalties on books from Vanderbilt University Press and McGraw&#x2010;Hill Medical Publishers. Dr Dresser has received payment for lectures, including service on speaker bureaus from Aventis, Astra Zeneca Canada, Boehringer Ingelheim, Bristol&#x2010;Myers Squibb, Merck Canada, and Servier.</p>
    </sec>
  </body>
  <back>
    <ref-list content-type="cited-references" id="jah31306-bibl-0001">
      <title>References</title>
      <ref id="jah31306-bib-0001">
        <label>1</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0001">
<string-name>
<surname>Mancini</surname>
<given-names>GB</given-names>
</string-name>, <string-name>
<surname>Tashakkor</surname>
<given-names>AY</given-names>
</string-name>, <string-name>
<surname>Baker</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bergeron</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Fitchett</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Frohlich</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Genest</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Gupta</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hegele</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Ng</surname>
<given-names>DS</given-names>
</string-name>, <string-name>
<surname>Pearson</surname>
<given-names>GJ</given-names>
</string-name>, <string-name>
<surname>Pope</surname>
<given-names>J</given-names>
</string-name>. <article-title>Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update</article-title>. <source>Can J Cardiol</source>. <year>2013</year>;<volume>29</volume>:<fpage>1553</fpage>&#x2013;<lpage>1568</lpage>.<pub-id pub-id-type="pmid">24267801</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0002">
        <label>2</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0002">
<string-name>
<surname>Stroes</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Thompson</surname>
<given-names>PD</given-names>
</string-name>, <string-name>
<surname>Corsini</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Vladutiu</surname>
<given-names>GD</given-names>
</string-name>, <string-name>
<surname>Raal</surname>
<given-names>FJ</given-names>
</string-name>, <string-name>
<surname>Ray</surname>
<given-names>KK</given-names>
</string-name>, <string-name>
<surname>Roden</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Stein</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Tokgozoglu</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Nordestgaard</surname>
<given-names>BG</given-names>
</string-name>, <string-name>
<surname>Bruckert</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>De</surname>
<given-names>BG</given-names>
</string-name>, <string-name>
<surname>Krauss</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Laufs</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Santos</surname>
<given-names>RD</given-names>
</string-name>, <string-name>
<surname>Hegele</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Hovingh</surname>
<given-names>GK</given-names>
</string-name>, <string-name>
<surname>Leiter</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Mach</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Marz</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Newman</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Wiklund</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Jacobson</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Catapano</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Chapman</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Ginsberg</surname>
<given-names>HN</given-names>
</string-name>. <article-title>Statin&#x2010;associated muscle symptoms: impact on statin therapy&#x2010;European Atherosclerosis Society Consensus Panel&#xA0;Statement on Assessment, Aetiology and Management</article-title>. <source>Eur Heart J</source>. <year>2015</year>;<volume>36</volume>:<fpage>1012</fpage>&#x2013;<lpage>1022</lpage>.<pub-id pub-id-type="pmid">25694464</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0003">
        <label>3</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0003">
<string-name>
<surname>McKenney</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Davidson</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Jacobson</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Guyton</surname>
<given-names>JR</given-names>
</string-name>; <collab collab-type="authors">National Lipid Association Statin Safety Assessment Task F</collab>
. <article-title>Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force</article-title>. <source>Am J Cardiol</source>. <year>2006</year>;<volume>97</volume>:<fpage>89C</fpage>&#x2013;<lpage>94C</lpage>.</mixed-citation>
      </ref>
      <ref id="jah31306-bib-0004">
        <label>4</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0004">
<string-name>
<surname>Armstrong</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>DC</given-names>
</string-name>, <string-name>
<surname>Westin</surname>
<given-names>GG</given-names>
</string-name>, <string-name>
<surname>Singh</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>McCoach</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Bang</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Yeo</surname>
<given-names>KK</given-names>
</string-name>, <string-name>
<surname>Anderson</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Amsterdam</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Laird</surname>
<given-names>JR</given-names>
</string-name>. <article-title>Adherence to guideline&#x2010;recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease</article-title>. <source>J Am Heart Assoc</source>. <year>2014</year>;<volume>3</volume>:<fpage>e000697</fpage> doi: <ext-link ext-link-type="doi" xlink:href="10.1161/JAHA.113.000697">10.1161/JAHA.113.000697</ext-link>.<pub-id pub-id-type="pmid">24721799</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0005">
        <label>5</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0005">
<string-name>
<surname>Baigent</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Blackwell</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Emberson</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Holland</surname>
<given-names>LE</given-names>
</string-name>, <string-name>
<surname>Reith</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Bhala</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Peto</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Barnes</surname>
<given-names>EH</given-names>
</string-name>, <string-name>
<surname>Keech</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Simes</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Collins</surname>
<given-names>R</given-names>
</string-name>. <article-title>Efficacy and safety of more intensive lowering of LDL cholesterol: a meta&#x2010;analysis of data from 170,000 participants in 26 randomised trials</article-title>. <source>Lancet</source>. <year>2010</year>;<volume>376</volume>:<fpage>1670</fpage>&#x2013;<lpage>1681</lpage>.<pub-id pub-id-type="pmid">21067804</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0006">
        <label>6</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0006">
<string-name>
<surname>Taylor</surname>
<given-names>FC</given-names>
</string-name>, <string-name>
<surname>Huffman</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ebrahim</surname>
<given-names>S</given-names>
</string-name>. <article-title>Statin therapy for primary prevention of cardiovascular disease</article-title>. <source>JAMA</source>. <year>2013</year>;<volume>310</volume>:<fpage>2451</fpage>&#x2013;<lpage>2452</lpage>.<pub-id pub-id-type="pmid">24276813</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0007">
        <label>7</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0007">
<string-name>
<surname>Stone</surname>
<given-names>NJ</given-names>
</string-name>, <string-name>
<surname>Robinson</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lichtenstein</surname>
<given-names>AH</given-names>
</string-name>, <string-name>
<surname>Bairey Merz</surname>
<given-names>CN</given-names>
</string-name>, <string-name>
<surname>Lloyd&#x2010;Jones</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Blum</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>McBride</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Eckel</surname>
<given-names>RH</given-names>
</string-name>, <string-name>
<surname>Schwartz</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Goldberg</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Shero</surname>
<given-names>ST</given-names>
</string-name>, <string-name>
<surname>Gordon</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>SC</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Levy</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Watson</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Wilson</surname>
<given-names>PW</given-names>
</string-name>. <article-title>2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines</article-title>. <source>J Am Coll Cardiol</source>. <year>2014</year>;<volume>63</volume>:<fpage>2889</fpage>&#x2013;<lpage>2934</lpage>.<pub-id pub-id-type="pmid">24239923</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0008">
        <label>8</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0008">
<string-name>
<surname>Robinson</surname>
<given-names>JG</given-names>
</string-name>. <article-title>Accumulating evidence for statins in primary prevention</article-title>. <source>JAMA</source>. <year>2013</year>;<volume>310</volume>:<fpage>2405</fpage>&#x2013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">24276744</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0009">
        <label>9</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0009">
<string-name>
<surname>Perreault</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Blais</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Dragomir</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bouchard</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Lalonde</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Laurier</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Collin</surname>
<given-names>J</given-names>
</string-name>. <article-title>Persistence and determinants of statin therapy among middle&#x2010;aged patients free of cardiovascular disease</article-title>. <source>Eur J Clin Pharmacol</source>. <year>2005</year>;<volume>61</volume>:<fpage>667</fpage>&#x2013;<lpage>674</lpage>.<pub-id pub-id-type="pmid">16151763</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0010">
        <label>10</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0010">
<string-name>
<surname>Perreault</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Blais</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Lamarre</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Dragomir</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Berbiche</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Lalonde</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Laurier</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>St&#x2010;Maurice</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Collin</surname>
<given-names>J</given-names>
</string-name>. <article-title>Persistence and determinants of statin therapy among middle&#x2010;aged patients for primary and secondary prevention</article-title>. <source>Br J Clin Pharmacol</source>. <year>2005</year>;<volume>59</volume>:<fpage>564</fpage>&#x2013;<lpage>573</lpage>.<pub-id pub-id-type="pmid">15842555</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0011">
        <label>11</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0011">
<string-name>
<surname>Simons</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Ortiz</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Calcino</surname>
<given-names>G</given-names>
</string-name>. <article-title>Long term persistence with statin therapy&#x2014;experience in Australia 2006&#x2013;2010</article-title>. <source>Aust Fam Physician</source>. <year>2011</year>;<volume>40</volume>:<fpage>319</fpage>&#x2013;<lpage>322</lpage>.<pub-id pub-id-type="pmid">21597553</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0012">
        <label>12</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0012">
<string-name>
<surname>Chodick</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Shalev</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Gerber</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Heymann</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Silber</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Simah</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Kokia</surname>
<given-names>E</given-names>
</string-name>. <article-title>Long&#x2010;term persistence with statin treatment in a not&#x2010;for&#x2010;profit health maintenance organization: a population&#x2010;based retrospective cohort study in Israel</article-title>. <source>Clin Ther</source>. <year>2008</year>;<volume>30</volume>:<fpage>2167</fpage>&#x2013;<lpage>2179</lpage>.<pub-id pub-id-type="pmid">19108805</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0013">
        <label>13</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0013">
<string-name>
<surname>Zhang</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Davies</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Radican</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Seck</surname>
<given-names>T</given-names>
</string-name>. <article-title>Compliance and persistence with concomitant statin and oral antihyperglycemic therapy</article-title>. <source>Am J Manag Care</source>. <year>2011</year>;<volume>17</volume>:<fpage>746</fpage>&#x2013;<lpage>752</lpage>.<pub-id pub-id-type="pmid">22084894</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0014">
        <label>14</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0014">
<string-name>
<surname>Haukka</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Niskanen</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Partonen</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>L&#xF6;nnqvist</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Tiihonen</surname>
<given-names>J</given-names>
</string-name>. <article-title>Statin usage and all&#x2010;cause and disease&#x2010;specific mortality in a nationwide study</article-title>. <source>Pharmacoepidemiol Drug Saf</source>. <year>2012</year>;<volume>21</volume>:<fpage>61</fpage>&#x2013;<lpage>69</lpage>.<pub-id pub-id-type="pmid">21956915</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0015">
        <label>15</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0015">
<string-name>
<surname>Degli Esposti</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Saragoni</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Batacchi</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Benemei</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Geppetti</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Sturani</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Buda</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Degli</surname>
<given-names>EE</given-names>
</string-name>. <article-title>Adherence to statin treatment and health outcomes in an Italian cohort of newly treated patients: results from an administrative database analysis</article-title>. <source>Clin Ther</source>. <year>2012</year>;<volume>34</volume>:<fpage>190</fpage>&#x2013;<lpage>199</lpage>.<pub-id pub-id-type="pmid">22284998</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0016">
        <label>16</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0016">
<string-name>
<surname>Zhang</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Plutzky</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Skentzos</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Morrison</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Mar</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Shubina</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Turchin</surname>
<given-names>A</given-names>
</string-name>. <article-title>Discontinuation of statins in routine care settings: a cohort study</article-title>. <source>Ann Intern Med</source>. <year>2013</year>;<volume>158</volume>:<fpage>526</fpage>&#x2013;<lpage>534</lpage>.<pub-id pub-id-type="pmid">23546564</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0017">
        <label>17</label>
        <mixed-citation publication-type="book" id="jah31306-cit-0017">
<string-name>
<surname>Spence</surname>
<given-names>JD</given-names>
</string-name>. <source>How to Prevent Your Stroke</source>. <publisher-loc>Nashville</publisher-loc>: <publisher-name>Vanderbilt University Press</publisher-name>; <year>2006</year>.</mixed-citation>
      </ref>
      <ref id="jah31306-bib-0018">
        <label>18</label>
        <mixed-citation publication-type="miscellaneous" id="jah31306-cit-0018">
<string-name>
<surname>Grundy</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Arai</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Barter</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Bersot</surname>
<given-names>TP</given-names>
</string-name>, <string-name>
<surname>Bettridge</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Carmena</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Cuevas</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Davidson</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Genest</surname>
<given-names>J</given-names>
</string-name>. <article-title>An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia</article-title>. <year>2013</year>;2013. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.athero.org/IASPositionPaper.asp">http://www.athero.org/IASPositionPaper.asp</ext-link>. Accessed August 17, 2015.</mixed-citation>
      </ref>
      <ref id="jah31306-bib-0019">
        <label>19</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0019">
<string-name>
<surname>Bader</surname>
<given-names>T</given-names>
</string-name>. <article-title>The myth of statin&#x2010;induced hepatotoxicity</article-title>. <source>Am J Gastroenterol</source>. <year>2010</year>;<volume>105</volume>:<fpage>978</fpage>&#x2013;<lpage>980</lpage>.<pub-id pub-id-type="pmid">20445507</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0020">
        <label>20</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0020">
<string-name>
<surname>Bader</surname>
<given-names>T</given-names>
</string-name>. <article-title>Liver tests are irrelevant when prescribing statins</article-title>. <source>Lancet</source>. <year>2010</year>;<volume>376</volume>:<fpage>1882</fpage>&#x2013;<lpage>1883</lpage>.<pub-id pub-id-type="pmid">21109303</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0021">
        <label>21</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0021">
<string-name>
<surname>Armitage</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bowman</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Collins</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Parish</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Tobert</surname>
<given-names>J</given-names>
</string-name>. <article-title>Effects of simvastatin 40&#xA0;mg daily on muscle and liver adverse effects in a 5&#x2010;year randomized placebo&#x2010;controlled trial in 20,536 high&#x2010;risk people</article-title>. <source>BMC Clin Pharmacol</source>. <year>2009</year>;<volume>9</volume>:<fpage>6</fpage>.<pub-id pub-id-type="pmid">19442259</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0022">
        <label>22</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0022">
<string-name>
<surname>Athyros</surname>
<given-names>VG</given-names>
</string-name>, <string-name>
<surname>Tziomalos</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Gossios</surname>
<given-names>TD</given-names>
</string-name>, <string-name>
<surname>Griva</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Anagnostis</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Kargiotis</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Pagourelias</surname>
<given-names>ED</given-names>
</string-name>, <string-name>
<surname>Theocharidou</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Karagiannis</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Mikhailidis</surname>
<given-names>DP</given-names>
</string-name>. <article-title>Safety and efficacy of long&#x2010;term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post&#x2010;hoc analysis</article-title>. <source>Lancet</source>. <year>2010</year>;<volume>376</volume>:<fpage>1916</fpage>&#x2013;<lpage>1922</lpage>.<pub-id pub-id-type="pmid">21109302</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0023">
        <label>23</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0023">
<string-name>
<surname>Spence</surname>
<given-names>JD</given-names>
</string-name>. <article-title>Statins do not cause intracerebral hemorrhage</article-title>. <source>Neurology</source>. <year>2012</year>;<volume>79</volume>:<fpage>1076</fpage>&#x2013;<lpage>1077</lpage>.<pub-id pub-id-type="pmid">22843275</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0024">
        <label>24</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0024">
<string-name>
<surname>Amarenco</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Bogousslavsky</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Callahan</surname>
<given-names>A</given-names>
<suffix>III</suffix>
</string-name>, <string-name>
<surname>Goldstein</surname>
<given-names>LB</given-names>
</string-name>, <string-name>
<surname>Hennerici</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rudolph</surname>
<given-names>AE</given-names>
</string-name>, <string-name>
<surname>Sillesen</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Simunovic</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Szarek</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Welch</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Zivin</surname>
<given-names>JA</given-names>
</string-name>; <collab collab-type="authors">Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators</collab>
. . <article-title>High&#x2010;dose atorvastatin after stroke or transient ischemic attack</article-title>. <source>N Engl J Med</source>. <year>2006</year>;<volume>355</volume>:<fpage>549</fpage>&#x2013;<lpage>559</lpage>.<pub-id pub-id-type="pmid">16899775</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0025">
        <label>25</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0025">
<string-name>
<surname>Spence</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Hackam</surname>
<given-names>DG</given-names>
</string-name>. <article-title>Response to letter by Hadjiev et&#xA0;al</article-title>. <source>Stroke</source>. <year>2011</year>;<volume>42</volume>:<fpage>e42</fpage>.</mixed-citation>
      </ref>
      <ref id="jah31306-bib-0026">
        <label>26</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0026">
<string-name>
<surname>Day</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Policeni</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Smoker</surname>
<given-names>WR</given-names>
</string-name>, <string-name>
<surname>Dobre</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Leira</surname>
<given-names>EC</given-names>
</string-name>, <string-name>
<surname>Davis</surname>
<given-names>PH</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Olalde</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Adams</surname>
<given-names>HP</given-names>
<suffix>Jr</suffix>
</string-name>. <article-title>Previous statin use is not associated with an increased prevalence or degree of gradient&#x2010;echo lesions in patients with acute ischemic stroke or transient ischemic attack</article-title>. <source>Stroke</source>. <year>2010</year>;<volume>42</volume>:<fpage>354</fpage>&#x2013;<lpage>358</lpage>.<pub-id pub-id-type="pmid">21164134</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0027">
        <label>27</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0027">
<string-name>
<surname>Hackam</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>Austin</surname>
<given-names>PC</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Juurlink</surname>
<given-names>DN</given-names>
</string-name>, <string-name>
<surname>Mamdani</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Paterson</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Hachinski</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Kapral</surname>
<given-names>MK</given-names>
</string-name>. <article-title>Statins and intracerebral hemorrhage: a retrospective cohort study</article-title>. <source>Arch Neurol</source>. <year>2012</year>;<volume>69</volume>:<fpage>39</fpage>&#x2013;<lpage>45</lpage>.<pub-id pub-id-type="pmid">21911657</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0028">
        <label>28</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0028">
<string-name>
<surname>Hackam</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>Woodward</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Newby</surname>
<given-names>LK</given-names>
</string-name>, <string-name>
<surname>Bhatt</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Shao</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>EE</given-names>
</string-name>, <string-name>
<surname>Donner</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Mamdani</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Douketis</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Arima</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Chalmers</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>MacMahon</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Tirschwell</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Psaty</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Bushnell</surname>
<given-names>CD</given-names>
</string-name>, <string-name>
<surname>Aguilar</surname>
<given-names>MI</given-names>
</string-name>, <string-name>
<surname>Capampangan</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Werring</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>De</surname>
<given-names>RP</given-names>
</string-name>, <string-name>
<surname>Viswanathan</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Danchin</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>YH</given-names>
</string-name>, <string-name>
<surname>Verdel</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Lai</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Kennedy</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Uchiyama</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Yamaguchi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ikeda</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Mrkobrada</surname>
<given-names>M</given-names>
</string-name>. <article-title>Statins and intracerebral hemorrhage: collaborative systematic review and meta&#x2010;analysis</article-title>. <source>Circulation</source>. <year>2011</year>;<volume>124</volume>:<fpage>2233</fpage>&#x2013;<lpage>2242</lpage>.<pub-id pub-id-type="pmid">22007076</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0029">
        <label>29</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0029">
<string-name>
<surname>Nardi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Engelter</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Strbian</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Sarikaya</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Arnold</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Casoni</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Ford</surname>
<given-names>GA</given-names>
</string-name>, <string-name>
<surname>Cordonnier</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Lyrer</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Bordet</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Soinne</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Gensicke</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Duriez</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Baumgartner</surname>
<given-names>RW</given-names>
</string-name>, <string-name>
<surname>Tatlisumak</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Leys</surname>
<given-names>D</given-names>
</string-name>. <article-title>Lipid profiles and outcome in patients treated by intravenous thrombolysis for cerebral ischemia</article-title>. <source>Neurology</source>. <year>2012</year>;<volume>79</volume>:<fpage>1101</fpage>&#x2013;<lpage>1108</lpage>.<pub-id pub-id-type="pmid">22843281</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0030">
        <label>30</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0030">
<string-name>
<surname>Rocco</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sykora</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ringleb</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Diedler</surname>
<given-names>J</given-names>
</string-name>. <article-title>Impact of statin use and lipid profile on symptomatic intracerebral haemorrhage, outcome and mortality after intravenous thrombolysis in acute stroke</article-title>. <source>Cerebrovasc Dis</source>. <year>2012</year>;<volume>33</volume>:<fpage>362</fpage>&#x2013;<lpage>368</lpage>.<pub-id pub-id-type="pmid">22433177</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0031">
        <label>31</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0031">
<string-name>
<surname>Uyttenboogaart</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Koch</surname>
<given-names>MW</given-names>
</string-name>, <string-name>
<surname>Koopman</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Vroomen</surname>
<given-names>PC</given-names>
</string-name>, <string-name>
<surname>Luijckx</surname>
<given-names>GJ</given-names>
</string-name>, <string-name>
<surname>De</surname>
<given-names>KJ</given-names>
</string-name>. <article-title>Lipid profile, statin use, and outcome after intravenous thrombolysis for acute ischaemic stroke</article-title>. <source>J Neurol</source>. <year>2008</year>;<volume>255</volume>:<fpage>875</fpage>&#x2013;<lpage>880</lpage>.<pub-id pub-id-type="pmid">18338194</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0032">
        <label>32</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0032">
<string-name>
<surname>Spence</surname>
<given-names>JD</given-names>
</string-name>. <article-title>Statins and cataracts: reverse causality?</article-title>
<source>Can J Cardiol</source>. <year>2015</year>;<volume>31</volume>:<fpage>691</fpage>.<pub-id pub-id-type="pmid">25795104</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0033">
        <label>33</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0033">
<string-name>
<surname>Muldoon</surname>
<given-names>MF</given-names>
</string-name>, <string-name>
<surname>Barger</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Ryan</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Flory</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Lehoczky</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Matthews</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Manuck</surname>
<given-names>SB</given-names>
</string-name>. <article-title>Effects of lovastatin on cognitive function and psychological well&#x2010;being</article-title>. <source>Am J Med</source>. <year>2000</year>;<volume>108</volume>:<fpage>538</fpage>&#x2013;<lpage>546</lpage>.<pub-id pub-id-type="pmid">10806282</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0034">
        <label>34</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0034">
<string-name>
<surname>Muldoon</surname>
<given-names>MF</given-names>
</string-name>, <string-name>
<surname>Ryan</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Sereika</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Flory</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Manuck</surname>
<given-names>SB</given-names>
</string-name>. <article-title>Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults</article-title>. <source>Am J Med</source>. <year>2004</year>;<volume>117</volume>:<fpage>823</fpage>&#x2013;<lpage>829</lpage>.<pub-id pub-id-type="pmid">15589485</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0035">
        <label>35</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0035">
<string-name>
<surname>Rea</surname>
<given-names>TD</given-names>
</string-name>, <string-name>
<surname>Breitner</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Psaty</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Fitzpatrick</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Lopez</surname>
<given-names>OL</given-names>
</string-name>, <string-name>
<surname>Newman</surname>
<given-names>AB</given-names>
</string-name>, <string-name>
<surname>Hazzard</surname>
<given-names>WR</given-names>
</string-name>, <string-name>
<surname>Zandi</surname>
<given-names>PP</given-names>
</string-name>, <string-name>
<surname>Burke</surname>
<given-names>GL</given-names>
</string-name>, <string-name>
<surname>Lyketsos</surname>
<given-names>CG</given-names>
</string-name>, <string-name>
<surname>Bernick</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kuller</surname>
<given-names>LH</given-names>
</string-name>. <article-title>Statin use and the risk of incident dementia: the Cardiovascular Health Study</article-title>. <source>Arch Neurol</source>. <year>2005</year>;<volume>62</volume>:<fpage>1047</fpage>&#x2013;<lpage>1051</lpage>.<pub-id pub-id-type="pmid">16009757</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0036">
        <label>36</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0036">
<string-name>
<surname>Bettermann</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Arnold</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Williamson</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Rapp</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Sink</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Toole</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Carlson</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Yasar</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Dekosky</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Burke</surname>
<given-names>GL</given-names>
</string-name>. <article-title>Statins, risk of dementia, and cognitive function: secondary analysis of the ginkgo evaluation of memory study</article-title>. <source>J Stroke Cerebrovasc Dis</source>. <year>2012</year>;<volume>21</volume>:<fpage>436</fpage>&#x2013;<lpage>444</lpage>.<pub-id pub-id-type="pmid">21236699</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0037">
        <label>37</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0037">
<string-name>
<surname>Glasser</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>Wadley</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Judd</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kana</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Prince</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Jenny</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Kissela</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Safford</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Prineas</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Howard</surname>
<given-names>G</given-names>
</string-name>. <article-title>The association of statin use and statin type and cognitive performance: analysis of the reasons for geographic and racial differences in stroke (REGARDS) study</article-title>. <source>Clin Cardiol</source>. <year>2010</year>;<volume>33</volume>:<fpage>280</fpage>&#x2013;<lpage>288</lpage>.<pub-id pub-id-type="pmid">20513066</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0038">
        <label>38</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0038">
<string-name>
<surname>Haag</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Hofman</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Koudstaal</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Stricker</surname>
<given-names>BH</given-names>
</string-name>, <string-name>
<surname>Breteler</surname>
<given-names>MM</given-names>
</string-name>. <article-title>Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>2009</year>;<volume>80</volume>:<fpage>13</fpage>&#x2013;<lpage>17</lpage>.<pub-id pub-id-type="pmid">18931004</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0039">
        <label>39</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0039">
<string-name>
<surname>Spence</surname>
<given-names>JD</given-names>
</string-name>. <article-title>Preventing dementia by treating hypertension and stroke</article-title>. <source>Hypertension</source>. <year>2004</year>;<volume>44</volume>:<fpage>20</fpage>&#x2013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">15173124</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0040">
        <label>40</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0040">
<string-name>
<surname>Song</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Nie</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Association of statin use with risk of dementia: a meta&#x2010;analysis of prospective cohort studies</article-title>. <source>Geriatr Gerontol Int</source>. <year>2013</year>;<volume>13</volume>:<fpage>817</fpage>&#x2013;<lpage>824</lpage>.<pub-id pub-id-type="pmid">23461525</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0041">
        <label>41</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0041">
<string-name>
<surname>Rojas&#x2010;Fernandez</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Cameron</surname>
<given-names>JC</given-names>
</string-name>. <article-title>Is statin&#x2010;associated cognitive impairment clinically relevant? A narrative review and clinical recommendations</article-title>. <source>Ann Pharmacother</source>. <year>2012</year>;<volume>46</volume>:<fpage>549</fpage>&#x2013;<lpage>557</lpage>.<pub-id pub-id-type="pmid">22474137</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0042">
        <label>42</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0042">
<string-name>
<surname>Jukema</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Cannon</surname>
<given-names>CP</given-names>
</string-name>, <string-name>
<surname>de Craen</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Westendorp</surname>
<given-names>RG</given-names>
</string-name>, <string-name>
<surname>Trompet</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Glasser</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>Wadley</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Judd</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kana</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Prince</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Jenny</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Kissela</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Safford</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Prineas</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Howard</surname>
<given-names>G</given-names>
</string-name>. <article-title>The controversies of statin therapy: weighing the evidence</article-title>. <source>J Am Coll Cardiol</source>. <year>2012</year>;<volume>33</volume>:<fpage>280</fpage>&#x2013;<lpage>288</lpage>.</mixed-citation>
      </ref>
      <ref id="jah31306-bib-0043">
        <label>43</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0043">
<string-name>
<surname>Swiger</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Manalac</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Blumenthal</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Blaha</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Martin</surname>
<given-names>SS</given-names>
</string-name>. <article-title>Statins and cognition: a systematic review and meta&#x2010;analysis of short&#x2010; and long&#x2010;term cognitive effects</article-title>. <source>Mayo Clin Proc</source>. <year>2013</year>;<volume>88</volume>:<fpage>1213</fpage>&#x2013;<lpage>1221</lpage>.<pub-id pub-id-type="pmid">24095248</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0044">
        <label>44</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0044">
<string-name>
<surname>Richardson</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Schoen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>French</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Umscheid</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Mitchell</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Arnold</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Heidenreich</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Rader</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Degoma</surname>
<given-names>EM</given-names>
</string-name>. <article-title>Statins and cognitive function: a systematic review</article-title>. <source>Ann Intern Med</source>. <year>2013</year>;<volume>159</volume>:<fpage>688</fpage>&#x2013;<lpage>697</lpage>.<pub-id pub-id-type="pmid">24247674</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0045">
        <label>45</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0045">
<string-name>
<surname>Patel</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Shariff</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bailey</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>Juurlink</surname>
<given-names>DN</given-names>
</string-name>, <string-name>
<surname>Gandhi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Mamdani</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gomes</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Fleet</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hwang</surname>
<given-names>YJ</given-names>
</string-name>, <string-name>
<surname>Garg</surname>
<given-names>AX</given-names>
</string-name>. <article-title>Statin toxicity from macrolide antibiotic coprescription: a population&#x2010;based cohort study</article-title>. <source>Ann Intern Med</source>. <year>2013</year>;<volume>158</volume>:<fpage>869</fpage>&#x2013;<lpage>876</lpage>.<pub-id pub-id-type="pmid">23778904</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0046">
        <label>46</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0046">
<string-name>
<surname>Alsheikh&#x2010;Ali</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Ambrose</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Kuvin</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>Karas</surname>
<given-names>RH</given-names>
</string-name>. <article-title>The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis</article-title>. <source>Circulation</source>. <year>2005</year>;<volume>111</volume>:<fpage>3051</fpage>&#x2013;<lpage>3057</lpage>.<pub-id pub-id-type="pmid">15911706</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0047">
        <label>47</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0047">
<string-name>
<surname>Kostapanos</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Milionis</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>Gazi</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Kostara</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Bairaktari</surname>
<given-names>ET</given-names>
</string-name>, <string-name>
<surname>Elisaf</surname>
<given-names>M</given-names>
</string-name>. <article-title>Rosuvastatin increases alpha&#x2010;1 microglobulin urinary excretion in patients with primary dyslipidemia</article-title>. <source>J Clin Pharmacol</source>. <year>2006</year>;<volume>46</volume>:<fpage>1337</fpage>&#x2013;<lpage>1343</lpage>.<pub-id pub-id-type="pmid">17050799</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0048">
        <label>48</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0048">
<string-name>
<surname>Sandhu</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Wiebe</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Fried</surname>
<given-names>LF</given-names>
</string-name>, <string-name>
<surname>Tonelli</surname>
<given-names>M</given-names>
</string-name>. <article-title>Statins for improving renal outcomes: a meta&#x2010;analysis</article-title>. <source>J Am Soc Nephrol</source>. <year>2006</year>;<volume>17</volume>:<fpage>2006</fpage>&#x2013;<lpage>2016</lpage>.<pub-id pub-id-type="pmid">16762986</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0049">
        <label>49</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0049">
<string-name>
<surname>Tonelli</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Moye</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Sacks</surname>
<given-names>FM</given-names>
</string-name>, <string-name>
<surname>Cole</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Curhan</surname>
<given-names>GC</given-names>
</string-name>. <article-title>Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease</article-title>. <source>J Am Soc Nephrol</source>. <year>2003</year>;<volume>14</volume>:<fpage>1605</fpage>&#x2013;<lpage>1613</lpage>.<pub-id pub-id-type="pmid">12761262</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0050">
        <label>50</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0050">
<string-name>
<surname>Wu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>An</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Dong</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>An</surname>
<given-names>F</given-names>
</string-name>. <article-title>Effects of rosuvastatin and atorvastatin on renal function: meta&#x2010;analysis</article-title>. <source>Circ J</source>. <year>2012</year>;<volume>76</volume>:<fpage>1259</fpage>&#x2013;<lpage>1266</lpage>.<pub-id pub-id-type="pmid">22382383</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0051">
        <label>51</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0051">
<string-name>
<surname>Savarese</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Musella</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Volpe</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Paneni</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Perrone&#x2010;Filardi</surname>
<given-names>P</given-names>
</string-name>. <article-title>Effects of atorvastatin and rosuvastatin on renal function: a meta&#x2010;analysis</article-title>. <source>Int J Cardiol</source>. <year>2013</year>;<volume>167</volume>:<fpage>2482</fpage>&#x2013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">22633671</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0052">
        <label>52</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0052">
<string-name>
<surname>Athyros</surname>
<given-names>VG</given-names>
</string-name>, <string-name>
<surname>Mikhailidis</surname>
<given-names>DP</given-names>
</string-name>, <string-name>
<surname>Papageorgiou</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Symeonidis</surname>
<given-names>AN</given-names>
</string-name>, <string-name>
<surname>Pehlivanidis</surname>
<given-names>AN</given-names>
</string-name>, <string-name>
<surname>Bouloukos</surname>
<given-names>VI</given-names>
</string-name>, <string-name>
<surname>Elisaf</surname>
<given-names>M</given-names>
</string-name>. <article-title>The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study</article-title>. <source>J Clin Pathol</source>. <year>2004</year>;<volume>57</volume>:<fpage>728</fpage>&#x2013;<lpage>734</lpage>.<pub-id pub-id-type="pmid">15220366</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0053">
        <label>53</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0053">
<string-name>
<surname>Mikus</surname>
<given-names>CR</given-names>
</string-name>, <string-name>
<surname>Boyle</surname>
<given-names>LJ</given-names>
</string-name>, <string-name>
<surname>Borengasser</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Oberlin</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Naples</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>Fletcher</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Meers</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Ruebel</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Laughlin</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Dellsperger</surname>
<given-names>KC</given-names>
</string-name>, <string-name>
<surname>Fadel</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Thyfault</surname>
<given-names>JP</given-names>
</string-name>. <article-title>Simvastatin impairs exercise training adaptations</article-title>. <source>J Am Coll Cardiol</source>. <year>2013</year>;<volume>62</volume>:<fpage>709</fpage>&#x2013;<lpage>714</lpage>.<pub-id pub-id-type="pmid">23583255</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0054">
        <label>54</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0054">
<string-name>
<surname>Riphagen</surname>
<given-names>IJ</given-names>
</string-name>, <string-name>
<surname>van der Veer</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Muskiet</surname>
<given-names>FA</given-names>
</string-name>, <string-name>
<surname>Dejongste</surname>
<given-names>MJ</given-names>
</string-name>. <article-title>Myopathy during statin therapy in the daily practice of an outpatient cardiology clinic: prevalence, predictors and relation with vitamin D</article-title>. <source>Curr Med Res Opin</source>. <year>2012</year>;<volume>28</volume>:<fpage>1247</fpage>&#x2013;<lpage>1252</lpage>.<pub-id pub-id-type="pmid">22686958</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0055">
        <label>55</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0055">
<string-name>
<surname>Bruckert</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Hayem</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Dejager</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Yau</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Begaud</surname>
<given-names>B</given-names>
</string-name>. <article-title>Mild to moderate&#xA0;muscular symptoms with high&#x2010;dosage statin therapy in hyperlipidemic&#xA0;patients&#x2013;the PRIMO study</article-title>. <source>Cardiovasc Drugs Ther</source>. <year>2005</year>;<volume>19</volume>:<fpage>403</fpage>&#x2013;<lpage>414</lpage>.<pub-id pub-id-type="pmid">16453090</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0056">
        <label>56</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0056">
<string-name>
<surname>Rosenbaum</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Dallongeville</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Sabouret</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Bruckert</surname>
<given-names>E</given-names>
</string-name>. <article-title>Discontinuation of statin therapy due to muscular side effects: a survey in real life</article-title>. <source>Nutr Metab Cardiovasc Dis</source>. <year>2013</year>;<volume>23</volume>:<fpage>871</fpage>&#x2013;<lpage>875</lpage>.<pub-id pub-id-type="pmid">22748604</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0057">
        <label>57</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0057">
<string-name>
<surname>Thompson</surname>
<given-names>PD</given-names>
</string-name>, <string-name>
<surname>Clarkson</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Karas</surname>
<given-names>RH</given-names>
</string-name>. <article-title>Statin&#x2010;associated myopathy</article-title>. <source>JAMA</source>. <year>2003</year>;<volume>289</volume>:<fpage>1681</fpage>&#x2013;<lpage>1690</lpage>.<pub-id pub-id-type="pmid">12672737</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0058">
        <label>58</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0058">
<string-name>
<surname>Vaklavas</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Chatzizisis</surname>
<given-names>YS</given-names>
</string-name>, <string-name>
<surname>Ziakas</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Zamboulis</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Giannoglou</surname>
<given-names>GD</given-names>
</string-name>. <article-title>Molecular basis of statin&#x2010;associated myopathy</article-title>. <source>Atherosclerosis</source>. <year>2009</year>;<volume>202</volume>:<fpage>18</fpage>&#x2013;<lpage>28</lpage>.<pub-id pub-id-type="pmid">18585718</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0059">
        <label>59</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0059">
<string-name>
<surname>Phillips</surname>
<given-names>PS</given-names>
</string-name>, <string-name>
<surname>Haas</surname>
<given-names>RH</given-names>
</string-name>. <article-title>Statin myopathy as a metabolic muscle disease</article-title>. <source>Expert Rev Cardiovasc Ther</source>. <year>2008</year>;<volume>6</volume>:<fpage>971</fpage>&#x2013;<lpage>978</lpage>.<pub-id pub-id-type="pmid">18666847</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0060">
        <label>60</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0060">
<string-name>
<surname>Needham</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mastaglia</surname>
<given-names>FL</given-names>
</string-name>, <string-name>
<surname>Stroes</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Thompson</surname>
<given-names>PD</given-names>
</string-name>, <string-name>
<surname>Corsini</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Vladutiu</surname>
<given-names>GD</given-names>
</string-name>, <string-name>
<surname>Raal</surname>
<given-names>FJ</given-names>
</string-name>, <string-name>
<surname>Ray</surname>
<given-names>KK</given-names>
</string-name>, <string-name>
<surname>Roden</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Stein</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Tokgozoglu</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Nordestgaard</surname>
<given-names>BG</given-names>
</string-name>, <string-name>
<surname>Bruckert</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>De</surname>
<given-names>BG</given-names>
</string-name>, <string-name>
<surname>Krauss</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Laufs</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Santos</surname>
<given-names>RD</given-names>
</string-name>, <string-name>
<surname>Hegele</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Hovingh</surname>
<given-names>GK</given-names>
</string-name>, <string-name>
<surname>Leiter</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Mach</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Marz</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Newman</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Wiklund</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Jacobson</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Catapano</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Chapman</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Ginsberg</surname>
<given-names>HN</given-names>
</string-name>. <article-title>Statin myotoxicity: a review of genetic susceptibility factors</article-title>. <source>Neuromuscul Disord</source>. <year>2014</year>;<volume>24</volume>:<fpage>4</fpage>&#x2013;<lpage>15</lpage>.<pub-id pub-id-type="pmid">24176465</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0061">
        <label>61</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0061">
<string-name>
<surname>Vladutiu</surname>
<given-names>GD</given-names>
</string-name>, <string-name>
<surname>Simmons</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Isackson</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Tarnopolsky</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Peltier</surname>
<given-names>WL</given-names>
</string-name>, <string-name>
<surname>Barboi</surname>
<given-names>AC</given-names>
</string-name>,&#xA0;<string-name>
<surname>Sripathi</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Wortmann</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Phillips</surname>
<given-names>PS</given-names>
</string-name>. <article-title>Genetic risk factors associated with lipid&#x2010;lowering drug&#x2010;induced myopathies</article-title>. <source>Muscle Nerve</source>. <year>2006</year>;<volume>34</volume>:<fpage>153</fpage>&#x2013;<lpage>162</lpage>.<pub-id pub-id-type="pmid">16671104</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0062">
        <label>62</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0062">
<string-name>
<surname>Baker</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Vladutiu</surname>
<given-names>GD</given-names>
</string-name>, <string-name>
<surname>Peltier</surname>
<given-names>WL</given-names>
</string-name>, <string-name>
<surname>Isackson</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Tarnopolsky</surname>
<given-names>MA</given-names>
</string-name>. <article-title>Metabolic myopathies discovered during investigations of statin myopathy</article-title>. <source>Can J Neurol Sci</source>. <year>2008</year>;<volume>35</volume>:<fpage>94</fpage>&#x2013;<lpage>97</lpage>.<pub-id pub-id-type="pmid">18380285</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0063">
        <label>63</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0063">
<string-name>
<surname>Golomb</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Evans</surname>
<given-names>MA</given-names>
</string-name>. <article-title>Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism</article-title>. <source>Am J Cardiovasc Drugs</source>. <year>2008</year>;<volume>8</volume>:<fpage>373</fpage>&#x2013;<lpage>418</lpage>.<pub-id pub-id-type="pmid">19159124</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0064">
        <label>64</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0064">
<string-name>
<surname>Parker</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Gregory</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Lorson</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Polk</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>White</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Thompson</surname>
<given-names>PD</given-names>
</string-name>. <article-title>A randomized trial of coenzyme Q10 in patients with statin myopathy: rationale and study design</article-title>. <source>J Clin Lipidol</source>. <year>2013</year>;<volume>7</volume>:<fpage>187</fpage>&#x2013;<lpage>193</lpage>.<pub-id pub-id-type="pmid">23725917</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0065">
        <label>65</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0065">
<string-name>
<surname>Vladutiu</surname>
<given-names>GD</given-names>
</string-name>. <article-title>Genetic predisposition to statin myopathy</article-title>. <source>Curr Opin Rheumatol</source>. <year>2008</year>;<volume>20</volume>:<fpage>648</fpage>&#x2013;<lpage>655</lpage>.<pub-id pub-id-type="pmid">18946323</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0066">
        <label>66</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0066">
<string-name>
<surname>Brewer</surname>
<given-names>HB</given-names>
<suffix>Jr</suffix>
</string-name>. <article-title>Benefit&#x2010;risk assessment of Rosuvastatin 10 to 40 milligrams</article-title>. <source>Am J Cardiol</source>. <year>2003</year>;<volume>92</volume>:<fpage>23K</fpage>&#x2013;<lpage>29K</lpage>.</mixed-citation>
      </ref>
      <ref id="jah31306-bib-0067">
        <label>67</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0067">
<string-name>
<surname>Wilke</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Ramsey</surname>
<given-names>LB</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>SG</given-names>
</string-name>, <string-name>
<surname>Maxwell</surname>
<given-names>WD</given-names>
</string-name>, <string-name>
<surname>McLeod</surname>
<given-names>HL</given-names>
</string-name>, <string-name>
<surname>Voora</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Krauss</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Roden</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Feng</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Cooper&#x2010;Dehoff</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Gong</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Klein</surname>
<given-names>TE</given-names>
</string-name>, <string-name>
<surname>Wadelius</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Niemi</surname>
<given-names>M</given-names>
</string-name>. <article-title>The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin&#x2010;induced myopathy</article-title>. <source>Clin Pharmacol Ther</source>. <year>2012</year>;<volume>92</volume>:<fpage>112</fpage>&#x2013;<lpage>117</lpage>.<pub-id pub-id-type="pmid">22617227</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0068">
        <label>68</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0068">
<string-name>
<surname>Garcia</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Reinoso</surname>
<given-names>RF</given-names>
</string-name>, <string-name>
<surname>Sanchez Navarro</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Prous</surname>
<given-names>JR</given-names>
</string-name>. <article-title>Clinical pharmacokinetics of statins</article-title>. <source>Methods Find Exp Clin Pharmacol</source>. <year>2003</year>;<volume>25</volume>:<fpage>457</fpage>&#x2013;<lpage>481</lpage>.<pub-id pub-id-type="pmid">12949632</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0069">
        <label>69</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0069">
<string-name>
<surname>Romaine</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>Bailey</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Hall</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Balmforth</surname>
<given-names>AJ</given-names>
</string-name>. <article-title>The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy</article-title>. <source>Pharmacogenomics J</source>. <year>2010</year>;<volume>10</volume>:<fpage>1</fpage>&#x2013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">19884908</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0070">
        <label>70</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0070">
<string-name>
<surname>Pasanen</surname>
<given-names>MK</given-names>
</string-name>, <string-name>
<surname>Neuvonen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Neuvonen</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Niemi</surname>
<given-names>M</given-names>
</string-name>. <article-title>SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid</article-title>. <source>Pharmacogenet Genomics</source>. <year>2006</year>;<volume>16</volume>:<fpage>873</fpage>&#x2013;<lpage>879</lpage>.<pub-id pub-id-type="pmid">17108811</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0071">
        <label>71</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0071">
<string-name>
<surname>Bellosta</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Paoletti</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Corsini</surname>
<given-names>A</given-names>
</string-name>. <article-title>Safety of statins: focus on clinical pharmacokinetics and drug interactions</article-title>. <source>Circulation</source>. <year>2004</year>;<volume>109</volume>:<fpage>III50</fpage>&#x2013;<lpage>III57</lpage>.<pub-id pub-id-type="pmid">15198967</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0072">
        <label>72</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0072">
<string-name>
<surname>Zhang</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Deng</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>XP</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Xie</surname>
<given-names>HT</given-names>
</string-name>, <string-name>
<surname>He</surname>
<given-names>FY</given-names>
</string-name>, <string-name>
<surname>Cao</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>YJ</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>HH</given-names>
</string-name>. <article-title>Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single&#x2010;blind, placebo&#x2010;controlled, crossover study</article-title>. <source>Clin Ther</source>. <year>2008</year>;<volume>30</volume>:<fpage>1283</fpage>&#x2013;<lpage>1289</lpage>.<pub-id pub-id-type="pmid">18691987</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0073">
        <label>73</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0073">
<string-name>
<surname>Neuvonen</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Niemi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Backman</surname>
<given-names>JT</given-names>
</string-name>. <article-title>Drug interactions with lipid&#x2010;lowering drugs: mechanisms and clinical relevance</article-title>. <source>Clin Pharmacol Ther</source>. <year>2006</year>;<volume>80</volume>:<fpage>565</fpage>&#x2013;<lpage>581</lpage>.<pub-id pub-id-type="pmid">17178259</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0074">
        <label>74</label>
        <mixed-citation publication-type="miscellaneous" id="jah31306-cit-0074">
<collab collab-type="authors">PharmGKB</collab>
. <year>2015</year> Available at: <ext-link ext-link-type="uri" xlink:href="https://www.pharmgkb.org/">https://www.pharmgkb.org/</ext-link>. Accessed August 17, 2015.</mixed-citation>
      </ref>
      <ref id="jah31306-bib-0075">
        <label>75</label>
        <mixed-citation publication-type="miscellaneous" id="jah31306-cit-0075">
<collab collab-type="authors">Monograph CPA</collab>
. <article-title>HMG&#x2010;CoA reductase inhibitors</article-title>. <year>2015</year> Available at: <ext-link ext-link-type="uri" xlink:href="http://www.pharmacists.ca/">http://www.pharmacists.ca/</ext-link>. Accessed August 17, 2015.</mixed-citation>
      </ref>
      <ref id="jah31306-bib-0076">
        <label>76</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0076">
<string-name>
<surname>Bailey</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>Spence</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Edgar</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Bayliff</surname>
<given-names>CD</given-names>
</string-name>, <string-name>
<surname>Arnold</surname>
<given-names>JM</given-names>
</string-name>. <article-title>Ethanol enhances the hemodynamic effects of felodipine</article-title>. <source>Clin Invest Med</source>. <year>1989</year>;<volume>12</volume>:<fpage>357</fpage>&#x2013;<lpage>362</lpage>.<pub-id pub-id-type="pmid">2612087</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0077">
        <label>77</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0077">
<string-name>
<surname>Bailey</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>Spence</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Munoz</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Arnold</surname>
<given-names>JM</given-names>
</string-name>. <article-title>Interaction of citrus juices with felodipine and nifedipine</article-title>. <source>Lancet</source>. <year>1991</year>;<volume>337</volume>:<fpage>268</fpage>&#x2013;<lpage>269</lpage>.<pub-id pub-id-type="pmid">1671113</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0078">
        <label>78</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0078">
<string-name>
<surname>Bailey</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>Malcolm</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Arnold</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Spence</surname>
<given-names>JD</given-names>
</string-name>. <article-title>Grapefruit juice&#x2010;drug interactions. 1998</article-title>. <source>Br J Clin Pharmacol</source>. <year>2004</year>;<volume>58</volume>:<fpage>S831</fpage>&#x2013;<lpage>S840</lpage>.<pub-id pub-id-type="pmid">15595979</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0079">
        <label>79</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0079">
<string-name>
<surname>Egan</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Colman</surname>
<given-names>E</given-names>
</string-name>. <article-title>Weighing the benefits of high&#x2010;dose simvastatin against the risk of myopathy</article-title>. <source>N Engl J Med</source>. <year>2011</year>;<volume>365</volume>:<fpage>285</fpage>&#x2013;<lpage>287</lpage>.<pub-id pub-id-type="pmid">21675881</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0080">
        <label>80</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0080">
<string-name>
<surname>Lilja</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Neuvonen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Neuvonen</surname>
<given-names>PJ</given-names>
</string-name>. <article-title>Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin</article-title>. <source>Br J Clin Pharmacol</source>. <year>2004</year>;<volume>58</volume>:<fpage>56</fpage>&#x2013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">15206993</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0081">
        <label>81</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0081">
<string-name>
<surname>Dreier</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Endres</surname>
<given-names>M</given-names>
</string-name>. <article-title>Statin&#x2010;associated rhabdomyolysis triggered by grapefruit consumption</article-title>. <source>Neurology</source>. <year>2004</year>;<volume>62</volume>:<fpage>670</fpage>.<pub-id pub-id-type="pmid">14981197</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0082">
        <label>82</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0082">
<string-name>
<surname>Kantola</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kivisto</surname>
<given-names>KT</given-names>
</string-name>, <string-name>
<surname>Neuvonen</surname>
<given-names>PJ</given-names>
</string-name>. <article-title>Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid</article-title>. <source>Clin Pharmacol Ther</source>. <year>1998</year>;<volume>63</volume>:<fpage>397</fpage>&#x2013;<lpage>402</lpage>.<pub-id pub-id-type="pmid">9585793</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0083">
        <label>83</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0083">
<string-name>
<surname>Lilja</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Kivisto</surname>
<given-names>KT</given-names>
</string-name>, <string-name>
<surname>Neuvonen</surname>
<given-names>PJ</given-names>
</string-name>. <article-title>Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin</article-title>. <source>Clin Pharmacol Ther</source>. <year>1999</year>;<volume>66</volume>:<fpage>118</fpage>&#x2013;<lpage>127</lpage>.<pub-id pub-id-type="pmid">10460065</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0084">
        <label>84</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0084">
<string-name>
<surname>Neuvonen</surname>
<given-names>PJ</given-names>
</string-name>. <article-title>Drug interactions with HMG&#x2010;CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics</article-title>. <source>Curr Opin Investig Drugs</source>. <year>2010</year>;<volume>11</volume>:<fpage>323</fpage>&#x2013;<lpage>332</lpage>.</mixed-citation>
      </ref>
      <ref id="jah31306-bib-0085">
        <label>85</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0085">
<string-name>
<surname>Spence</surname>
<given-names>JD</given-names>
</string-name>. <article-title>Drug interactions with grapefruit: whose responsibility is it to warn the public? [see comments]</article-title>. <source>Clin Pharmacol Ther</source>. <year>1997</year>;<volume>61</volume>:<fpage>395</fpage>&#x2013;<lpage>400</lpage>.<pub-id pub-id-type="pmid">9129556</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0086">
        <label>86</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0086">
<string-name>
<surname>Sattar</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Preiss</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Murray</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Welsh</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Buckley</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>de Craen</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Seshasai</surname>
<given-names>SR</given-names>
</string-name>, <string-name>
<surname>McMurray</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Freeman</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Jukema</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Macfarlane</surname>
<given-names>PW</given-names>
</string-name>, <string-name>
<surname>Packard</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Stott</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Westendorp</surname>
<given-names>RG</given-names>
</string-name>, <string-name>
<surname>Shepherd</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Davis</surname>
<given-names>BR</given-names>
</string-name>, <string-name>
<surname>Pressel</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Marchioli</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Marfisi</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Maggioni</surname>
<given-names>AP</given-names>
</string-name>, <string-name>
<surname>Tavazzi</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Tognoni</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Kjekshus</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Pedersen</surname>
<given-names>TR</given-names>
</string-name>, <string-name>
<surname>Cook</surname>
<given-names>TJ</given-names>
</string-name>, <string-name>
<surname>Gotto</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Clearfield</surname>
<given-names>MB</given-names>
</string-name>, <string-name>
<surname>Downs</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Nakamura</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Ohashi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Mizuno</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ray</surname>
<given-names>KK</given-names>
</string-name>, <string-name>
<surname>Ford</surname>
<given-names>I</given-names>
</string-name>. <article-title>Statins and risk of incident diabetes: a collaborative meta&#x2010;analysis of randomised statin trials</article-title>. <source>Lancet</source>. <year>2010</year>;<volume>375</volume>:<fpage>735</fpage>&#x2013;<lpage>742</lpage>.<pub-id pub-id-type="pmid">20167359</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0087">
        <label>87</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0087">
<string-name>
<surname>Preiss</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Seshasai</surname>
<given-names>SR</given-names>
</string-name>, <string-name>
<surname>Welsh</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Murphy</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Ho</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Waters</surname>
<given-names>DD</given-names>
</string-name>, <string-name>
<surname>DeMicco</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Barter</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Cannon</surname>
<given-names>CP</given-names>
</string-name>, <string-name>
<surname>Sabatine</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Braunwald</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Kastelein</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>de Lemos</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Blazing</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Pedersen</surname>
<given-names>TR</given-names>
</string-name>, <string-name>
<surname>Tikkanen</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Sattar</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Ray</surname>
<given-names>KK</given-names>
</string-name>. <article-title>Risk of incident diabetes with intensive&#x2010;dose compared with moderate&#x2010;dose statin therapy: a meta&#x2010;analysis</article-title>. <source>JAMA</source>. <year>2011</year>;<volume>305</volume>:<fpage>2556</fpage>&#x2013;<lpage>2564</lpage>.<pub-id pub-id-type="pmid">21693744</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0088">
        <label>88</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0088">
<string-name>
<surname>Ridker</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Pradhan</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>MacFadyen</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Libby</surname>
<given-names>P</given-names>
</string-name>. <article-title>Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial</article-title>. <source>Lancet</source>. <year>2012</year>;<volume>380</volume>:<fpage>565</fpage>&#x2013;<lpage>571</lpage>.<pub-id pub-id-type="pmid">22883507</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0089">
        <label>89</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0089">
<string-name>
<surname>Dormuth</surname>
<given-names>CR</given-names>
</string-name>, <string-name>
<surname>Filion</surname>
<given-names>KB</given-names>
</string-name>, <string-name>
<surname>Paterson</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>James</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Teare</surname>
<given-names>GF</given-names>
</string-name>, <string-name>
<surname>Raymond</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Tamim</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Lipscombe</surname>
<given-names>L</given-names>
</string-name>; <collab collab-type="authors">Investigators ftCNfODESC</collab>
. <article-title>Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases</article-title>. <source>BMJ</source>. <year>2014</year>;<volume>348</volume>:<fpage>g3244</fpage>.<pub-id pub-id-type="pmid">24874977</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0090">
        <label>90</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0090">
<string-name>
<surname>Davidson</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>McGarry</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Bettis</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Melani</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Lipka</surname>
<given-names>LJ</given-names>
</string-name>, <string-name>
<surname>LeBeaut</surname>
<given-names>AP</given-names>
</string-name>, <string-name>
<surname>Suresh</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Veltri</surname>
<given-names>EP</given-names>
</string-name>. <article-title>Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia</article-title>. <source>J Am Coll Cardiol</source>. <year>2002</year>;<volume>40</volume>:<fpage>2125</fpage>&#x2013;<lpage>2134</lpage>.<pub-id pub-id-type="pmid">12505224</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0091">
        <label>91</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0091">
<string-name>
<surname>Amarenco</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lavallee</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Touboul</surname>
<given-names>PJ</given-names>
</string-name>. <article-title>Statins and stroke prevention</article-title>. <source>Cerebrovasc Dis</source>. <year>2004</year>;<volume>17</volume>(<issue>suppl 1</issue>):<fpage>81</fpage>&#x2013;<lpage>88</lpage>.<pub-id pub-id-type="pmid">14694285</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0092">
        <label>92</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0092">
<string-name>
<surname>Zacho</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Tybjaerg&#x2010;Hansen</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Jensen</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Grande</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Sillesen</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Nordestgaard</surname>
<given-names>BG</given-names>
</string-name>. <article-title>Genetically elevated C&#x2010;reactive protein and ischemic vascular disease</article-title>. <source>N Engl J Med</source>. <year>2008</year>;<volume>359</volume>:<fpage>1897</fpage>&#x2013;<lpage>1908</lpage>.<pub-id pub-id-type="pmid">18971492</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0093">
        <label>93</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0093">
<string-name>
<surname>Wensley</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Gao</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Burgess</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kaptoge</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Di</surname>
<given-names>AE</given-names>
</string-name>, <string-name>
<surname>Shah</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Engert</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Clarke</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Davey&#x2010;Smith</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Nordestgaard</surname>
<given-names>BG</given-names>
</string-name>, <string-name>
<surname>Saleheen</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Samani</surname>
<given-names>NJ</given-names>
</string-name>, <string-name>
<surname>Sandhu</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Anand</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Pepys</surname>
<given-names>MB</given-names>
</string-name>, <string-name>
<surname>Smeeth</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Whittaker</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Casas</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Thompson</surname>
<given-names>SG</given-names>
</string-name>, <string-name>
<surname>Hingorani</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Danesh</surname>
<given-names>J</given-names>
</string-name>. <article-title>Association between C reactive protein and coronary heart disease: Mendelian randomisation analysis based on individual participant data</article-title>. <source>BMJ</source>. <year>2011</year>;<volume>342</volume>:<fpage>d548</fpage>.<pub-id pub-id-type="pmid">21325005</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0094">
        <label>94</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0094">
<string-name>
<surname>Jonathan</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Derrick</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Emma</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Sarah</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>John</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Jane</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Rory</surname>
<given-names>C</given-names>
</string-name>. <article-title>C&#x2010;reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study</article-title>. <source>Lancet</source>. <year>2011</year>;<volume>377</volume>:<fpage>469</fpage>&#x2013;<lpage>476</lpage>.<pub-id pub-id-type="pmid">21277016</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0095">
        <label>95</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0095">
<string-name>
<surname>Sever</surname>
<given-names>PS</given-names>
</string-name>, <string-name>
<surname>Poulter</surname>
<given-names>NR</given-names>
</string-name>, <string-name>
<surname>Chang</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Hingorani</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Thom</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Hughes</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Welsh</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Sattar</surname>
<given-names>N</given-names>
</string-name>. <article-title>Evaluation of C&#x2010;reactive protein prior to and on&#x2010;treatment as a predictor of benefit from atorvastatin: observations from the Anglo&#x2010;Scandinavian Cardiac Outcomes Trial</article-title>. <source>Eur Heart J</source>. <year>2012</year>;<volume>33</volume>:<fpage>486</fpage>&#x2013;<lpage>94</lpage>.<pub-id pub-id-type="pmid">21798891</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0096">
        <label>96</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0096">
<string-name>
<surname>Cannon</surname>
<given-names>CP</given-names>
</string-name>, <string-name>
<surname>Blazing</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Giugliano</surname>
<given-names>RP</given-names>
</string-name>, <string-name>
<surname>McCagg</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>White</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Theroux</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Darius</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Lewis</surname>
<given-names>BS</given-names>
</string-name>, <string-name>
<surname>Ophuis</surname>
<given-names>TO</given-names>
</string-name>, <string-name>
<surname>Jukema</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>De Ferrari</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Ruzyllo</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>De</surname>
<given-names>LP</given-names>
</string-name>, <string-name>
<surname>Im</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Bohula</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Reist</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Wiviott</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Tershakovec</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Musliner</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Braunwald</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Califf</surname>
<given-names>RM</given-names>
</string-name>; <collab collab-type="authors">IMPROVE&#x2010;IT Investigators</collab>
. <article-title>Ezetimibe added to statin therapy after acute coronary syndromes</article-title>. <source>N Engl J Med</source>. <year>2015</year>;<volume>372</volume>:<fpage>2387</fpage>&#x2013;<lpage>2397</lpage>.<pub-id pub-id-type="pmid">26039521</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0097">
        <label>97</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0097">
<string-name>
<surname>Watts</surname>
<given-names>GF</given-names>
</string-name>, <string-name>
<surname>Ooi</surname>
<given-names>EM</given-names>
</string-name>. <article-title>Balancing the cardiometabolic benefits and risks of statins</article-title>. <source>Lancet</source>. <year>2012</year>;<volume>380</volume>:<fpage>541</fpage>&#x2013;<lpage>543</lpage>.<pub-id pub-id-type="pmid">22883491</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0098">
        <label>98</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0098">
<string-name>
<surname>Malaguarnera</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Vacante</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Motta</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Malaguarnera</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>VG</given-names>
</string-name>, <string-name>
<surname>Galvano</surname>
<given-names>F</given-names>
</string-name>. <article-title>Effect of L&#x2010;carnitine on the size of low&#x2010;density lipoprotein particles in type 2 diabetes mellitus patients treated with simvastatin</article-title>. <source>Metabolism</source>. <year>2009</year>;<volume>58</volume>:<fpage>1618</fpage>&#x2013;<lpage>1623</lpage>.<pub-id pub-id-type="pmid">19604523</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0099">
        <label>99</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0099">
<string-name>
<surname>Galvano</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>VG</given-names>
</string-name>, <string-name>
<surname>Malaguarnera</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Avitabile</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Antic</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Vacante</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Malaguarnera</surname>
<given-names>M</given-names>
</string-name>. <article-title>Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus</article-title>. <source>Expert Opin Pharmacother</source>. <year>2009</year>;<volume>10</volume>:<fpage>1875</fpage>&#x2013;<lpage>1882</lpage>.<pub-id pub-id-type="pmid">19618992</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0100">
        <label>100</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0100">
<string-name>
<surname>Ruggenenti</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>van der Meer</surname>
<given-names>IM</given-names>
</string-name>, <string-name>
<surname>Remuzzi</surname>
<given-names>G</given-names>
</string-name>. <article-title>Oral acetyl&#x2010;L&#x2010;carnitine therapy and insulin resistance</article-title>. <source>Hypertension</source>. <year>2010</year>;<volume>55</volume>:<fpage>e26</fpage>.<pub-id pub-id-type="pmid">20439816</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0101">
        <label>101</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0101">
<string-name>
<surname>Reuter</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Evans</surname>
<given-names>AM</given-names>
</string-name>. <article-title>Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects</article-title>. <source>Clin Pharmacokinet</source>. <year>2012</year>;<volume>51</volume>:<fpage>553</fpage>&#x2013;<lpage>572</lpage>.<pub-id pub-id-type="pmid">22804748</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0102">
        <label>102</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0102">
<string-name>
<surname>Vladutiu</surname>
<given-names>GD</given-names>
</string-name>, <string-name>
<surname>Simmons</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Isackson</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Tarnopolsky</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Peltier</surname>
<given-names>WL</given-names>
</string-name>, <string-name>
<surname>Barboi</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Sripathi</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Wortmann</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Phillips</surname>
<given-names>PS</given-names>
</string-name>. <article-title>Genetic risk factors associated with lipid&#x2010;lowering drug&#x2010;induced myopathies</article-title>. <source>Muscle Nerve</source>. <year>2006</year>;<volume>5734</volume>:<fpage>153</fpage>&#x2013;<lpage>162</lpage>.<pub-id pub-id-type="pmid">16671104</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0103">
        <label>103</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0103">
<string-name>
<surname>DiMauro</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Schon</surname>
<given-names>EA</given-names>
</string-name>. <article-title>Mitochondrial respiratory&#x2010;chain diseases</article-title>. <source>N Engl J Med</source>. <year>2003</year>;<volume>348</volume>:<fpage>2656</fpage>&#x2013;<lpage>2668</lpage>.<pub-id pub-id-type="pmid">12826641</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0104">
        <label>104</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0104">
<string-name>
<surname>Koopman</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Willems</surname>
<given-names>PH</given-names>
</string-name>, <string-name>
<surname>Smeitink</surname>
<given-names>JA</given-names>
</string-name>. <article-title>Monogenic mitochondrial disorders</article-title>. <source>N Engl J Med</source>. <year>2012</year>;<volume>366</volume>:<fpage>1132</fpage>&#x2013;<lpage>1141</lpage>.<pub-id pub-id-type="pmid">22435372</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0105">
        <label>105</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0105">
<string-name>
<surname>Mangravite</surname>
<given-names>LM</given-names>
</string-name>, <string-name>
<surname>Engelhardt</surname>
<given-names>BE</given-names>
</string-name>, <string-name>
<surname>Medina</surname>
<given-names>MW</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>CD</given-names>
</string-name>, <string-name>
<surname>Chasman</surname>
<given-names>DI</given-names>
</string-name>, <string-name>
<surname>Mecham</surname>
<given-names>BH</given-names>
</string-name>, <string-name>
<surname>Howie</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Shim</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Naidoo</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Feng</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Rieder</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>YD</given-names>
</string-name>, <string-name>
<surname>Rotter</surname>
<given-names>JI</given-names>
</string-name>, <string-name>
<surname>Ridker</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Hopewell</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Parish</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Armitage</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Collins</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Wilke</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Nickerson</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Stephens</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Krauss</surname>
<given-names>RM</given-names>
</string-name>. <article-title>A statin&#x2010;dependent QTL for GATM expression is associated with statin&#x2010;induced myopathy</article-title>. <source>Nature</source>. <year>2013</year>;<volume>502</volume>:<fpage>377</fpage>&#x2013;<lpage>380</lpage>.<pub-id pub-id-type="pmid">23995691</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0106">
        <label>106</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0106">
<string-name>
<surname>Ruano</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Windemuth</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>AH</given-names>
</string-name>, <string-name>
<surname>Kane</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Malloy</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Pullinger</surname>
<given-names>CR</given-names>
</string-name>, <string-name>
<surname>Kocherla</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bogaard</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Gordon</surname>
<given-names>BR</given-names>
</string-name>, <string-name>
<surname>Holford</surname>
<given-names>TR</given-names>
</string-name>, <string-name>
<surname>Gupta</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Seip</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Thompson</surname>
<given-names>PD</given-names>
</string-name>. <article-title>Mechanisms of statin&#x2010;induced myalgia assessed by physiogenomic associations</article-title>. <source>Atherosclerosis</source>. <year>2011</year>;<volume>218</volume>:<fpage>451</fpage>&#x2013;<lpage>456</lpage>.<pub-id pub-id-type="pmid">21868014</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0107">
        <label>107</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0107">
<string-name>
<surname>Link</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Parish</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Armitage</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bowman</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Heath</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Matsuda</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Gut</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Lathrop</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Collins</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Armitage</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bowman</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Collins</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Parish</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Tobert</surname>
<given-names>J</given-names>
</string-name>. <article-title>SLCO1B1 variants and statin&#x2010;induced myopathy&#x2013;a genomewide study</article-title>. <source>N Engl J Med</source>. <year>2008</year>;<volume>359</volume>:<fpage>789</fpage>&#x2013;<lpage>799</lpage>.<pub-id pub-id-type="pmid">18650507</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0108">
        <label>108</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0108">
<string-name>
<surname>Knauer</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Urquhart</surname>
<given-names>BL</given-names>
</string-name>, <string-name>
<surname>Meyer zu Schwabedissen</surname>
<given-names>HE</given-names>
</string-name>, <string-name>
<surname>Schwarz</surname>
<given-names>UI</given-names>
</string-name>, <string-name>
<surname>Lemke</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Leake</surname>
<given-names>BF</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>RB</given-names>
</string-name>, <string-name>
<surname>Tirona</surname>
<given-names>RG</given-names>
</string-name>. <article-title>Human skeletal muscle drug transporters determine local exposure and toxicity of statins</article-title>. <source>Circ Res</source>. <year>2010</year>;<volume>106</volume>:<fpage>297</fpage>&#x2013;<lpage>306</lpage>.<pub-id pub-id-type="pmid">19940267</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0109">
        <label>109</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0109">
<string-name>
<surname>Bogiatzi</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Spence</surname>
<given-names>JD</given-names>
</string-name>. <article-title>Ezetimibe and regression of carotid atherosclerosis: importance of measuring plaque burden</article-title>. <source>Stroke</source>. <year>2012</year>;<volume>43</volume>:<fpage>1153</fpage>&#x2013;<lpage>1155</lpage>.<pub-id pub-id-type="pmid">22223239</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0110">
        <label>110</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0110">
<string-name>
<surname>Finn</surname>
<given-names>AV</given-names>
</string-name>, <string-name>
<surname>Kolodgie</surname>
<given-names>FD</given-names>
</string-name>, <string-name>
<surname>Virmani</surname>
<given-names>R</given-names>
</string-name>. <article-title>Correlation between carotid intimal/medial thickness and atherosclerosis. A point of view from pathology</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2010</year>;<volume>30</volume>:<fpage>177</fpage>&#x2013;<lpage>181</lpage>.<pub-id pub-id-type="pmid">19679833</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0111">
        <label>111</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0111">
<string-name>
<surname>Spence</surname>
<given-names>JD</given-names>
</string-name>. <article-title>Carotid ultrasound phenotypes are biologically distinct</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2015</year>;<volume>35</volume>:<fpage>1910</fpage>&#x2013;<lpage>1913</lpage>.<pub-id pub-id-type="pmid">26310810</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0112">
        <label>112</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0112">
<string-name>
<surname>Tsujita</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Sugiyama</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Sumida</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Shimomura</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Yamashita</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Yamanaga</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Komura</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Sakamoto</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Oka</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Nakao</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Nakamura</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ishihara</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Matsui</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Sakaino</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Nakamura</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Yamamoto</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Koide</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Matsumura</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Fujimoto</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Tsunoda</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Morikami</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Matsuyama</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Oshima</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kaikita</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Hokimoto</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ogawa</surname>
<given-names>H</given-names>
</string-name>. <article-title>Impact of dual lipid&#x2010;lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the Multicenter Randomized Controlled PRECISE&#x2010;IVUS Trial</article-title>. <source>J Am Coll Cardiol</source>. <year>2015</year>;<volume>66</volume>:<fpage>495</fpage>&#x2013;<lpage>507</lpage>.<pub-id pub-id-type="pmid">26227186</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0113">
        <label>113</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0113">
<string-name>
<surname>Caso</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Kelly</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>McNurlan</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Lawson</surname>
<given-names>WE</given-names>
</string-name>. <article-title>Effect of coenzyme q10 on myopathic symptoms in patients treated with statins</article-title>. <source>Am J Cardiol</source>. <year>2007</year>;<volume>99</volume>:<fpage>1409</fpage>&#x2013;<lpage>1412</lpage>.<pub-id pub-id-type="pmid">17493470</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0114">
        <label>114</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0114">
<string-name>
<surname>Nielsen</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Pareek</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Henriksen</surname>
<given-names>JE</given-names>
</string-name>. [<article-title>Reduced synthesis of coenzyme Q10 may cause statin related myopathy</article-title>]. <source>Ugeskr Laeger</source>. <year>2011</year>;<volume>173</volume>:<fpage>2943</fpage>&#x2013;<lpage>2948</lpage>.<pub-id pub-id-type="pmid">22094213</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0115">
        <label>115</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0115">
<string-name>
<surname>Banach</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Serban</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Sahebkar</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ursoniu</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Rysz</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Muntner</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Toth</surname>
<given-names>PP</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>SR</given-names>
</string-name>, <string-name>
<surname>Rizzo</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Glasser</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>Lip</surname>
<given-names>GY</given-names>
</string-name>, <string-name>
<surname>Dragan</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Mikhailidis</surname>
<given-names>DP</given-names>
</string-name>; <collab collab-type="authors">Lipid and Blood Pressure Meta&#x2010;analysis Collaboration G</collab>
. <article-title>Effects of coenzyme Q10 on statin&#x2010;induced myopathy: a meta&#x2010;analysis of randomized controlled trials</article-title>. <source>Mayo Clin Proc</source>. <year>2015</year>;<volume>90</volume>:<fpage>24</fpage>&#x2013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">25440725</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0116">
        <label>116</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0116">
<string-name>
<surname>Banach</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Serban</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Ursoniu</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Rysz</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Muntner</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Toth</surname>
<given-names>PP</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>SR</given-names>
</string-name>, <string-name>
<surname>Rizzo</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Glasser</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>Watts</surname>
<given-names>GF</given-names>
</string-name>, <string-name>
<surname>Blumenthal</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Lip</surname>
<given-names>GY</given-names>
</string-name>, <string-name>
<surname>Mikhailidis</surname>
<given-names>DP</given-names>
</string-name>, <string-name>
<surname>Sahebkar</surname>
<given-names>A</given-names>
</string-name>; <collab collab-type="authors">Lipid and Blood Pressure Meta&#x2010;analysis Collaboration G</collab>
. <article-title>Statin therapy and plasma coenzyme Q10 concentrations&#x2010;A systematic review and meta&#x2010;analysis of placebo&#x2010;controlled trials</article-title>. <source>Pharmacol Res</source>. <year>2015</year>;<volume>99</volume>:<fpage>329</fpage>&#x2013;<lpage>336</lpage>.<pub-id pub-id-type="pmid">26192349</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0117">
        <label>117</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0117">
<string-name>
<surname>Deichmann</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Lavie</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Andrews</surname>
<given-names>S</given-names>
</string-name>. <article-title>Coenzyme q10 and statin&#x2010;induced mitochondrial dysfunction</article-title>. <source>Ochsner J</source>. <year>2010</year>;<volume>10</volume>:<fpage>16</fpage>&#x2013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">21603349</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0118">
        <label>118</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0118">
<string-name>
<surname>Mizuno</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Tanaka</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Nozaki</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Mizuma</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Ataka</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Tahara</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Sugino</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Shirai</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kajimoto</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kuratsune</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kajimoto</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Watanabe</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Antifatigue effects of coenzyme Q10 during physical fatigue</article-title>. <source>Nutrition</source>. <year>2008</year>;<volume>24</volume>:<fpage>293</fpage>&#x2013;<lpage>299</lpage>.<pub-id pub-id-type="pmid">18272335</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0119">
        <label>119</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0119">
<string-name>
<surname>Bookstaver</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Burkhalter</surname>
<given-names>NA</given-names>
</string-name>, <string-name>
<surname>Hatzigeorgiou</surname>
<given-names>C</given-names>
</string-name>. <article-title>Effect of coenzyme Q10 supplementation on statin&#x2010;induced myalgias</article-title>. <source>Am J Cardiol</source>. <year>2012</year>;<volume>110</volume>:<fpage>526</fpage>&#x2013;<lpage>529</lpage>.<pub-id pub-id-type="pmid">22608359</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0120">
        <label>120</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0120">
<string-name>
<surname>Fedacko</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Pella</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Fedackova</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Hanninen</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Tuomainen</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Jarcuska</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lopuchovsky</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Jedlickova</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Merkovska</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Littarru</surname>
<given-names>GP</given-names>
</string-name>. <article-title>Coenzyme Q(10) and selenium in statin&#x2010;associated myopathy treatment</article-title>. <source>Can J Physiol Pharmacol</source>. <year>2013</year>;<volume>91</volume>:<fpage>165</fpage>&#x2013;<lpage>170</lpage>.<pub-id pub-id-type="pmid">23458201</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0121">
        <label>121</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0121">
<string-name>
<surname>Muraki</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Miyashita</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Mitsuishi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tamaki</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tanaka</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Itoh</surname>
<given-names>H</given-names>
</string-name>. <article-title>Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin&#x2010;treated mice and increases exercise endurance</article-title>. <source>J Appl Physiol</source>. <year>2012</year>;<volume>113</volume>:<fpage>479</fpage>&#x2013;<lpage>486</lpage>.<pub-id pub-id-type="pmid">22653988</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0122">
        <label>122</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0122">
<string-name>
<surname>DiMauro</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hirano</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Schon</surname>
<given-names>EA</given-names>
</string-name>. <article-title>Approaches to the treatment of mitochondrial diseases</article-title>. <source>Muscle Nerve</source>. <year>2006</year>;<volume>34</volume>:<fpage>265</fpage>&#x2013;<lpage>283</lpage>.<pub-id pub-id-type="pmid">16810684</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0123">
        <label>123</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0123">
<string-name>
<surname>Baker</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Tarnopolsky</surname>
<given-names>MA</given-names>
</string-name>. <article-title>Targeting cellular energy production in neurological disorders</article-title>. <source>Expert Opin Investig Drugs</source>. <year>2003</year>;<volume>12</volume>:<fpage>1655</fpage>&#x2013;<lpage>1679</lpage>.</mixed-citation>
      </ref>
      <ref id="jah31306-bib-0124">
        <label>124</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0124">
<string-name>
<surname>Arduini</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Peschechera</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Giannessi</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Carminati</surname>
<given-names>P</given-names>
</string-name>. <article-title>Improvement of statin&#x2010;associated myotoxicity by L&#x2010;carnitine</article-title>. <source>J Thromb Haemost</source>. <year>2004</year>;<volume>2</volume>:<fpage>2270</fpage>&#x2013;<lpage>2271</lpage>.<pub-id pub-id-type="pmid">15613049</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0125">
        <label>125</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0125">
<string-name>
<surname>Koeth</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Levison</surname>
<given-names>BS</given-names>
</string-name>, <string-name>
<surname>Buffa</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Org</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Sheehy</surname>
<given-names>BT</given-names>
</string-name>, <string-name>
<surname>Britt</surname>
<given-names>EB</given-names>
</string-name>, <string-name>
<surname>Fu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Didonato</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>GD</given-names>
</string-name>, <string-name>
<surname>Lewis</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Warrier</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Krauss</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Tang</surname>
<given-names>WH</given-names>
</string-name>, <string-name>
<surname>Bushman</surname>
<given-names>FD</given-names>
</string-name>, <string-name>
<surname>Lusis</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Hazen</surname>
<given-names>SL</given-names>
</string-name>. <article-title>Intestinal microbiota metabolism of L&#x2010;carnitine, a nutrient in red meat, promotes atherosclerosis</article-title>. <source>Nat Med</source>. <year>2013</year>;<volume>19</volume>:<fpage>576</fpage>&#x2013;<lpage>585</lpage>.<pub-id pub-id-type="pmid">23563705</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0126">
        <label>126</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0126">
<string-name>
<surname>Johri</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Heyland</surname>
<given-names>DK</given-names>
</string-name>, <string-name>
<surname>Hetu</surname>
<given-names>MF</given-names>
</string-name>, <string-name>
<surname>Crawford</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Spence</surname>
<given-names>JD</given-names>
</string-name>. <article-title>Carnitine therapy for the treatment of metabolic syndrome and cardiovascular disease: evidence and controversies</article-title>. <source>Nutr Metab Cardiovasc Dis</source>. <year>2014</year>;<volume>24</volume>:<fpage>808</fpage>&#x2013;<lpage>814</lpage>.<pub-id pub-id-type="pmid">24837277</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0127">
        <label>127</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0127">
<string-name>
<surname>Spence</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Eliasziw</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>DiCicco</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hackam</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>Galil</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Lohmann</surname>
<given-names>T</given-names>
</string-name>. <article-title>Carotid plaque area: a tool for targeting and evaluating vascular preventive therapy</article-title>. <source>Stroke</source>. <year>2002</year>;<volume>33</volume>:<fpage>2916</fpage>&#x2013;<lpage>2922</lpage>.<pub-id pub-id-type="pmid">12468791</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0128">
        <label>128</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0128">
<string-name>
<surname>Johnsen</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Mathiesen</surname>
<given-names>EB</given-names>
</string-name>, <string-name>
<surname>Joakimsen</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Stensland</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Wilsgaard</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Lochen</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Njolstad</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Arnesen</surname>
<given-names>E</given-names>
</string-name>. <article-title>Carotid atherosclerosis is a stronger predictor of myocardial infarction in women than in men: a 6&#x2010;year follow&#x2010;up study of 6226 persons: the Tromso Study</article-title>. <source>Stroke</source>. <year>2007</year>;<volume>38</volume>:<fpage>2873</fpage>&#x2013;<lpage>2880</lpage>.<pub-id pub-id-type="pmid">17901390</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0129">
        <label>129</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0129">
<string-name>
<surname>Mathiesen</surname>
<given-names>EB</given-names>
</string-name>, <string-name>
<surname>Johnsen</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Wilsgaard</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Bonaa</surname>
<given-names>KH</given-names>
</string-name>, <string-name>
<surname>Lochen</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Njolstad</surname>
<given-names>I</given-names>
</string-name>. <article-title>Carotid plaque area and intima&#x2010;media thickness in prediction of first&#x2010;ever ischemic stroke: a 10&#x2010;year follow&#x2010;Up of 6584 men and women: the Tromso Study</article-title>. <source>Stroke</source>. <year>2011</year>;<volume>42</volume>:<fpage>972</fpage>&#x2013;<lpage>978</lpage>.<pub-id pub-id-type="pmid">21311059</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0130">
        <label>130</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0130">
<string-name>
<surname>Spence</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Hackam</surname>
<given-names>DG</given-names>
</string-name>. <article-title>Treating arteries instead of risk factors: a paradigm change in management of atherosclerosis</article-title>. <source>Stroke</source>. <year>2010</year>;<volume>41</volume>:<fpage>1193</fpage>&#x2013;<lpage>1199</lpage>.<pub-id pub-id-type="pmid">20413738</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0131">
        <label>131</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0131">
<string-name>
<surname>Spence</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Coates</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Tamayo</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Munoz</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Hackam</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>DiCicco</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>DesRoches</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bogiatzi</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Klein</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Madrenas</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hegele</surname>
<given-names>RA</given-names>
</string-name>. <article-title>Effects of intensive medical therapy on microemboli and cardiovascular risk in asymptomatic carotid stenosis</article-title>. <source>Arch Neurol</source>. <year>2010</year>;<volume>67</volume>:<fpage>180</fpage>&#x2013;<lpage>186</lpage>.<pub-id pub-id-type="pmid">20008646</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0132">
        <label>132</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0132">
<string-name>
<surname>Stein</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Mellis</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Yancopoulos</surname>
<given-names>GD</given-names>
</string-name>, <string-name>
<surname>Stahl</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Logan</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>WB</given-names>
</string-name>, <string-name>
<surname>Lisbon</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Guttierrez</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Webb</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Du</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kranz</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Gasparino</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Swergold</surname>
<given-names>GD</given-names>
</string-name>. <article-title>Effect of a monoclonal antibody to PCSK9 on LDL cholesterol</article-title>. <source>N Engl J Med</source>. <year>2012</year>;<volume>366</volume>:<fpage>1108</fpage>&#x2013;<lpage>1118</lpage>.<pub-id pub-id-type="pmid">22435370</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0133">
        <label>133</label>
        <mixed-citation publication-type="book" id="jah31306-cit-0133">
<collab collab-type="authors">Review IfCaE</collab>
. <article-title>PCSK9 inhibitors for treatment of high cholesterol: effectiveness, value, and value&#x2010;based price benchmarks: draft report</article-title>. <publisher-name>Institute for Clinical and Economic Review</publisher-name>
<year>2015</year> Available at: <ext-link ext-link-type="uri" xlink:href="http://cepac.icer-review.org/wp-content/uploads/2015/04/PCSK9_Draft_Report_0908152.pdf">http://cepac.icer-review.org/wp-content/uploads/2015/04/PCSK9_Draft_Report_0908152.pdf</ext-link>. Accessed August 17, 2015.</mixed-citation>
      </ref>
      <ref id="jah31306-bib-0134">
        <label>134</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0134">
<string-name>
<surname>Cannon</surname>
<given-names>CP</given-names>
</string-name>, <string-name>
<surname>Shah</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Dansky</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Davidson</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Brinton</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Gotto</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Stepanavage</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>SX</given-names>
</string-name>, <string-name>
<surname>Gibbons</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Ashraf</surname>
<given-names>TB</given-names>
</string-name>, <string-name>
<surname>Zafarino</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Mitchel</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Barter</surname>
<given-names>P</given-names>
</string-name>; <collab collab-type="authors">Investigators DtEaT</collab>
. <article-title>Safety of anacetrapib in patients with or at high risk for coronary heart disease</article-title>. <source>N Engl J Med</source>. <year>2010</year>;<volume>363</volume>:<fpage>2406</fpage>&#x2013;<lpage>2415</lpage>.<pub-id pub-id-type="pmid">21082868</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0135">
        <label>135</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0135">
<string-name>
<surname>Fitzgerald</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Frank&#x2010;Kamenetsky</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Shulga&#x2010;Morskaya</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Liebow</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bettencourt</surname>
<given-names>BR</given-names>
</string-name>, <string-name>
<surname>Sutherland</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Hutabarat</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Clausen</surname>
<given-names>VA</given-names>
</string-name>, <string-name>
<surname>Karsten</surname>
<given-names>V</given-names>
</string-name>,&#xA0;<string-name>
<surname>Cehelsky</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Nochur</surname>
<given-names>SV</given-names>
</string-name>, <string-name>
<surname>Kotelianski</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Horton</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Mant</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Chiesa</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ritter</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Munisamy</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Vaishnaw</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Gollob</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Simon</surname>
<given-names>A</given-names>
</string-name>. <article-title>Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single&#x2010;blind, placebo&#x2010;controlled, phase 1 trial</article-title>. <source>Lancet</source>. <year>2013</year>;<volume>383</volume>:<fpage>60</fpage>&#x2013;<lpage>68</lpage>.<pub-id pub-id-type="pmid">24094767</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0136">
        <label>136</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0136">
<string-name>
<surname>Huang</surname>
<given-names>LZ</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>
<given-names>HB</given-names>
</string-name>. <article-title>Novel LDL&#x2010;oriented pharmacotherapeutical strategies</article-title>. <source>Pharmacol Res</source>. <year>2012</year>;<volume>65</volume>:<fpage>402</fpage>&#x2013;<lpage>410</lpage>.<pub-id pub-id-type="pmid">22306845</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0137">
        <label>137</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0137">
<string-name>
<surname>Lee</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Hegele</surname>
<given-names>RA</given-names>
</string-name>. <article-title>Current phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia</article-title>. <source>Expert Opin Investig Drugs</source>. <year>2013</year>;<volume>2013</volume>:<fpage>1411</fpage>&#x2013;<lpage>1423</lpage>.</mixed-citation>
      </ref>
      <ref id="jah31306-bib-0138">
        <label>138</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0138">
<string-name>
<surname>Sahebkar</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Watts</surname>
<given-names>GF</given-names>
</string-name>. <article-title>New therapies targeting apoB metabolism for high&#x2010;risk patients with inherited dyslipidaemias: what can the clinician expect?</article-title>
<source>Cardiovasc Drugs Ther</source>. <year>2013</year>;<volume>27</volume>:<fpage>559</fpage>&#x2013;<lpage>567</lpage>.<pub-id pub-id-type="pmid">23913122</pub-id></mixed-citation>
      </ref>
      <ref id="jah31306-bib-0139">
        <label>139</label>
        <mixed-citation publication-type="journal" id="jah31306-cit-0139">
<string-name>
<surname>Kouronakis</surname>
<given-names>AP</given-names>
</string-name>, <string-name>
<surname>Katselou</surname>
<given-names>MG</given-names>
</string-name>, <string-name>
<surname>Matralis</surname>
<given-names>AN</given-names>
</string-name>, <string-name>
<surname>Ladopoulou</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Bavavea</surname>
<given-names>E</given-names>
</string-name>. <article-title>Squalene synthase inhibitors: an update on the search for new antihyperlipidemic and antiatherosclerotic agents</article-title>. <source>Curr Med Chem</source>. <year>2011</year>;<volume>18</volume>:<fpage>4418</fpage>&#x2013;<lpage>4439</lpage>.<pub-id pub-id-type="pmid">21864285</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
